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Abstract 
Numerous recurrent cytogenetic aberrations have been found in childhood acute 
leukaemias. Many of them have prognostic impact and their contributory role in 
the design of treatment has been valuable. Patients have been classified to 
different risk groups according to the existing criteria but the groups have, 
however, remained heterogeneous. Moreover, little is known about the causes 
of leukaemia at the molecular level. 
In this thesis, DNA copy number changes were first studied in 19 children 
with acute myeloid leukaemia (AML) and 72 children with acute lymphoblastic 
leukaemia (ALL) using comparative genomic hybridisation (CGH). In addition, 
the suitability of the method for diagnostics of these diseases was investigated. 
In AML, the CGH results agreed well with the conventional cytogenetic results, 
but did not give any additional information to the karyotypes. In ALL, CGH 
supplemented standard cytogenetic findings in about half of the cases. 
Therefore, routine use of the method is recommended for children at the 
diagnostic stage of ALL. 
In childhood ALL, the most common DNA copy number changes were gains 
of whole chromosomes, most frequently affecting chromosomes 21, 18, X, 10, 
17, 14, 4, 6 and 8 (14-25%). High-level amplifications were detected only in 
two patients (3%). Chromosome 21 was involved in both cases with 
amplifications, with minimal common region 21q22-qter. The most common 
losses were seen at chromosomal arms 9p (13%) and 12p (11%), with minimal 
common regions 9p22-pter and 12p13-pter, respectively. 
In order to investigate whether the AML1 gene, located at 21q22, is a target 
of the CGH amplifications, fluorescence in situ hybridisation (FISH) with 
AML1-specific probe was performed for 112 childhood ALL cases. As a novel 
finding in ALL, high-level amplification of AML1 was detected in three (2.7%) 
of the patients. These three patients also showed high-level amplification at 
21q22 by CGH. In addition, 37 patients (33%) had one or two extra copies of 
AML1, apparently reflecting the incidence of the gain of whole chromosome 21. 
Translocation t(12;21) resulting in the fusion of the TEL and AML1 genes, is 
the most common translocation in childhood ALL. Moreover, the 12p13-pter 
region, harbouring TEL (12p13), shows frequent loss by CGH. The non-
translocated TEL allele is known to be often deleted in patients with t(12;21). 
Gene-specific FISH was carried out in order to investigate whether the loss at 
12p is associated with the TEL-AML1 fusion and the TEL deletion. From the 
nine patients with 12p loss, the fusion was detected in eight of the cases and one 
allele of TEL was deleted in all cases. In addition, all cases showed favourable 
prognostic features and a trend to better overall survival compared to 70 
patients with no loss at 12p. 
Finally, gene expression profiles of the leukaemic blasts of 17 children with 
ALL were studied using cDNA array technology. The analysis of 415 genes 
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related to the function of blood cells or their precursors revealed over-
expression compared to mature B-cell reference in several myeloid-specific 
genes (S100A12, RNASE2, GCSFR, PRTN3 and CLC). The over-expressed 
genes included also AML1, LCP2 and FGF6. 
Many of the findings of this thesis, predominantly those in childhood ALL, 
are likely to have a role in the development or progression of leukaemia. The 
information obtained may further be employed in studies of the pathogenesis 
and treatment stratification of childhood ALL. 
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Introduction 
Leukaemia is a haematological malignancy, in which malignant blood cells or 
their precursors proliferate without control and accumulate in bone marrow and 
blood. Leukaemias are divided into acute and chronic types, which are further 
divided into lymphoblastic and myeloid types depending on the haematopoietic 
lineage of the cells involved. Leukaemia is the most common type of cancer in 
children. The great majority of childhood leukaemias are of the acute type, 
acute lymphoblastic leukaemia (ALL) comprising 80-85% of childhood cases 
and acute myeloid leukaemia (AML) 10-15% (http://www.cancerregistry.fi). 
The malignant transformation of a cell occurs as the consequence of changes 
in its genetic material. We know today a large number of recurrent cytogenetic 
aberrations, mainly translocations, specific to a certain type or even a subtype of 
leukaemia. Some of them have been shown to be prognostically significant, and 
they are utilized in the design of treatment [for review, see (Ma et al., 1999)]. 
For example, in childhood ALL, translocation t(12;21) has been associated with 
favourable outcome, and the patients with the aberration are usually treated with 
less intensive chemotherapy to avoid the side effects of the treatment. On the 
other hand, patients with translocation t(9;22) or t(4;11) are considered to have 
poor prognosis and need high-dose chemotherapy with stem cell transplantation 
to be cured. Despite the extensive knowledge of cytogenetic aberrations, little is 
known about the molecular changes that eventually lead to malignant 
transformation of the cell and to the development of leukaemia. 
In the risk classification of childhood ALL, not only cytogenetic alterations, 
but also many other factors are taken into account. These include, for example, 
white blood cell count (WBC) at diagnosis, age, response to primary therapy 
and the phenotype of the blasts (precursor-B cell / immature B cell / T cell) 
(Gustafsson et al., 2000). The groups of patients formed according to the 
existing criteria remain, however, quite heterogeneous as regards the outcome 
of the patients, leading to excessive treatment of some patients and failure of 
treatment in others.  
Several new methods to study genetic alterations have been developed in 
recent years. One of them is comparative genomic hybridisation (CGH), which 
enables genome-wide search for gained and lost chromosomal regions. CGH 
has been applied both in research and diagnostics. An even more powerful 
research tool is the novel DNA array technology, which allows the study of 
expression changes in hundreds to thousands of genes in a single experiment. 
The new techniques have already helped and will help us to understand the 
molecular events causing leukaemia, and to identify new prognostic markers for 
more individualised treatment of the patients. 
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Review of the literature 
1. Normal development of blood cells 
The development of blood cells is called haematopoiesis. Human 
haematopoiesis occurs mainly in the bone marrow, where pluripotent 
haematopoietic stem cells diverge both into new self-like cells and into 
differentiating stem cells. Through numerous divisions and differentiation, the 
differentiating stem cells develop into all types of blood cells (Hoffbrand and 
Pettit, 1993; Roitt et al., 1996). 
Haematopoiesis can be divided into two main lineages: myeloid and 
lymphoid. The myeloid lineage produces monocytes, macrophages, neutrophils, 
eosinophils, basophils, red blood cells and platelets. The lymphoid lineage gives 
rise to B lymphocytes alias B cells, T lymphocytes alias T cells and natural 
killer (NK) cells. (Roitt et al., 1996). 
The division, survival, life span, lineage commitment and differentiation of 
the haematopoietic cells are controlled by various growth factors as well as the 
interaction between the cells and their microenvironment. The effects of these 
factors are transmitted through cell surface receptor molecules into the cell 
where they cause changes in the function of transcription factors and, thus, in 
the activity of genes. 
2. Leukaemias 
A haematological malignancy arises when something goes wrong in the 
regulation of the division or the life span of a blood cell or its precursor. The 
cell starts to proliferate uncontrollably and forms a large cell population derived 
from a single cell. Haematological malignancies include leukaemias, 
lymphomas, multiple myeloma and myelodysplastic syndromes. A typical 
feature of leukaemias is that the cells accumulate in the bone marrow and blood.  
Leukaemias are divided into acute and chronic types, which are further 
classified into lymphoid and myeloid types depending on the cell lineage 
represented by the leukaemic clone.  In acute leukaemias (acute lymphoblastic 
leukaemia and acute myeloid leukaemia) the malignant cells are typically 
immature blast cells that are unable to differentiate. In the chronic lymphocytic 
leukaemia the malignant cells are morphologically mature and in chronic 
myeloid leukaemia, though derived from primitive cells, the differentiation of 
leukaemic cells is almost normal in the first stage of the disease. 
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3. Childhood leukaemias 
In 1998, 55 new cases of leukaemia in 0- to 19-year-olds were diagnosed in 
Finland (http://www.cancerregistry.fi). As mentioned, the most common type of 
childhood leukaemia is acute lymphoblastic leukaemia (ALL) (80-85%) and the 
second most common acute myeloid leukaemia (AML) (10-15%). Chronic 
myeloid leukaemia (CML) is very rare in children. Chronic lymphatic 
leukaemia (CLL), the most common type of leukaemia in adults, is not found in 
children. 
3.1. Childhood acute lymphoblastic leukaemia (ALL) 
The division of acute leukaemias to subtypes is based on immunophenotyping, 
morphology of the leukaemic cells and cytogenetic aberrations. In 
immunophenotyping or surface antigen studies, the cell type of the leukaemic 
blasts is identified with monoclonal antibodies. In 80-85% of childhood ALL 
cases, the abnormal clone represents an early stage of B-cell lineage. Three 
different forms of ALL are derived from B-cell precursors: “early precursor-B 
cell ALL”, “common ALL” and “precursor-B cell ALL” (Jaffe et al., 2001). 
The earliest cell type gives rise to early precursor-B cell ALL, which comprises 
most of infant ALL. In the most common type of childhood ALL, accordingly 
tagged common ALL, leukaemic blasts express CD10 antigen (CALLA) on the 
surface. In precursor-B cell ALL the blasts express immunoglobulins in the 
cytoplasm. In rare cases of childhood ALL, the leukaemic clone represents a 
more developed B cell with immunoglobulins on cell surface, and the disease is 
known as “Burkitt leukaemia”. In 15% of the patients, the leukaemic blasts are 
derived from the precursors of T-cell lineage, forming a subtype called 
“precursor-T cell ALL” (Jaffe et al., 2001). 
Childhood ALL is divided into risk groups according to prognostic factors. 
The Nordic classification consists of five risk groups: standard risk, 
intermediate risk, high risk, very high risk and infants (Gustafsson et al., 2000). 
The risks are classified in relation to the probability of relapse, i.e., the 
recurrence of the disease. At present, the risk classification is mostly based on 
white blood cell count (WBC), age, immunophenotype, genetic aberrations and 
response to treatment. The prognostic impacts of some genetic aberrations are 
discussed in Chapter 5. 
ALL is treated with chemotherapy and the cases with poor prognosis also 
with stem cell transplantation. The form and intensity of the treatment are 
determined based on the risk group. Patients with good or standard risk may be 
given less intensive conventional chemotherapy in order to minimise the side 
effects of the treatment, whereas patients with high risk may receive intensive 
treatment including stem cell transplantation. Therefore the differences in the 
overall outcomes between the different risk groups have reduced in recent years. 
The first aim of the treatment is to reach remission, a condition in which the 
clinical symptoms have disappeared and no leukaemic cells can be detected by 
conventional methods. Short-term side effects of the treatment are increased 
Review of the literature 
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predisposition to infections, increased danger of haemorrhage, and nausea. 
Long-term side effects include disorders in growth and development, and in 
boys, in fertility. Secondary cancers caused by the therapy also appear. The 
treatment of childhood ALL takes 2-2.5 years. The treatment results have 
significantly improved during the past two decades, and at present up to 80% of 
the childhood patients recover (Jaffe et al., 2001). The rate is much higher than 
in adults with ALL, of whom only 30-40% are cured [reviewed in (Pui and 
Evans, 1998)]. 
3.2. Childhood acute myeloid leukaemia (AML) 
The classification of AML consists of four major categories: (1) AML with 
recurrent genetic abnormalities, (2) AML with multilineage dysplasia, (3) 
therapy-related AML and (4) AML not otherwise categorized (Jaffe et al., 
2001). The most common genetic abnormalities of AML, included in category 
1, are t(8;21), inv(16) or t(16;16), t(15;17) and 11q23 abnormalities. Category 4 
encompasses cases that do not fulfil the criteria in any of the previous groups. 
The subclassification in this group is primarily based on morphologic and 
cytochemical features of the leukaemic blasts and the degree of their 
maturation. 
AML is often preceded by myelodysplastic syndrome. Myelodysplastic 
syndromes are a group of blood diseases with sliding boundary to AML, and in 
many cases they progress to AML. The progression is caused by clonal 
evolution, the appearance of new genetic alterations in the abnormal cell. 
In AML the prognosis is worse than in ALL - only about 40% of children 
with AML can be cured [(Pui, 1995) and references therein]. Genetic 
aberrations are the most important factor determining the prognosis and the 
choice of treatment. Chemotherapy is the cornerstone of treatment also in AML. 
Conventional chemotherapy is more intensive than in ALL but the total 
duration of the treatment is shorter, lasting usually from seven to ten months. 
For patients with an HLA-identical sibling available as donor, stem cell 
transplantation is usually recommended in the first remission.  
4. Aetiology of childhood leukaemias 
4.1. Prenatal origin 
The first or initiating event in childhood leukaemia often seems to be a 
translocation, which occurs already during foetal development (for information 
about translocations, see Chapter 5.1). This is suggested by findings from pairs 
of identical twins with leukaemia who share the same non-inherited gene fusion 
with identical breakpoints (infants with MLL fusions or older children with 
TEL-AML1 fusion; about TEL-AML1, see Chapter 5.1.1) (Ford et al., 1993; 
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Wiemels et al., 1999b). In addition, the same fusion gene that is seen in the 
patient’s leukaemic cells is often present in blood already at birth when the 
child is still disease-free. These studies suggest leukaemia to be foetal in origin 
in all cases of infant leukaemia (with fusions of MLL), in most cases of the 
common form of childhood ALL (with TEL-AML fusion), and in about half of 
the cases of childhood AML (with AML1-ETO fusion) (Gale et al., 1997; 
Wiemels et al., 1999a; Wiemels et al., 2002). 
In the case of infant leukaemia, the concordance of both of identical twins 
having leukaemia seems to be almost 100%. However, if one of the identical 
twins has leukaemia at 2-6 years of age, the risk of the other to get it is only 
about 5%. This suggests that the development of leukaemia requires at least one 
additional genetic event after birth besides the initial translocation (“two hit” 
model). The TEL-AML1 fusion is the most common gene fusion of childhood 
ALL (see Chapter 5.1.1). Screening of newborn has shown the frequency of the 
TEL-AML1 fusion to be as high as about 1%. The rate constitutes 100 times the 
risk of TEL-AML1-positive leukaemia, which suggests the second “hit” or the 
appearance of the additional genetic aberration to be a rare event [reviewed in 
(Greaves, 2002)]. 
4.2. Inherited predisposition and environmental 
factors 
The genetic aberrations leading to leukaemia are not likely to be caused by a 
single factor but rather by an interaction of exposure to some factor/s with 
inherited genetic predisposition (Greaves, 2002). Although the cause in most 
cases of childhood leukaemia is not known, certain factors have been suggested 
to contribute to susceptibility. 
Hereditary factors are likely to have a role in the predisposition to childhood 
leukaemia. The family history of cancer may be a risk factor for childhood 
ALL, which is supported by a recent study showing association of childhood 
ALL both with family history of haematological neoplasm and of solid tumour 
(Perrillat et al., 2001). The association was particularly clear when restricted to 
family history of AML. In addition, the inherited variation of some specific 
genes has been shown to influence the susceptibility of childhood leukaemia. 
The risk of infant leukaemias with the MLL (mixed lineage leukaemia) gene 
rearrangement has been associated with the polymorphism of NQO1 
(NAD(P)H:quinone oxidoreductase), an enzyme that detoxifies quinones 
(Wiemels et al., 1999c), and with the polymorphism of MTHFR 
(methylenetetrahydrofolate reductase), an important enzyme in folate 
metabolism (Wiemels et al., 2001). According to preliminary evidence, HLA 
class II alleles, important in immunity, contribute to predisposition to childhood 
ALL in boys [(Greaves, 2002) and a reference therein]. 
Up to 5% of acute leukaemia cases are associated with inherited, 
predisposing genetic syndromes [for review, see (Mizutani, 1998)]. Many of 
these disorders, like the Li Fraumeni syndrome, Bloom syndrome and ataxia 
telangiectasia, are associated with abnormalities in DNA repair or tumour 
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suppressor mechanisms. The incidence of leukaemia is also significantly higher 
in individuals with the Down syndrome with an extra chromosome 21. In 
addition, some genetic bone marrow failure syndromes, such as Fanconi 
anaemia, entail an increased risk to leukaemia. Another example is familial 
platelet disorder caused by haploinsufficiency of the AML1 gene (see Chapter 
5.1.1), which predisposes to AML (Song et al., 1999). 
Viruses have been shown to cause leukaemia in several different animals. In 
humans, HTLV-1 virus (human T-cell lymphotropic virus 1) infections have 
been connected with the development of adult T-cell ALL [reviewed in 
(Greaves, 1997)]. Considerable, although indirect, evidence exists that many 
childhood leukaemias, especially those in the childhood peak of common ALL, 
are caused by a rare, abnormal response to a common infection. This kind of 
response may happen as a consequence of either population mixing or 
“delayed” mixing with infectious carriers [(Greaves, 1997) and references 
therein].   
Ionising radiation has been found to predispose to acute leukaemia. This is 
proved by the high incidence of leukaemia in Japanese survivors from the 
explosion area of nuclear bombs and secondary leukaemias in the individuals 
treated by radiotherapy [(Greaves, 1997) and references therein]. A transient 
increase in the incidence of infant acute leukaemia was suggested in northern 
Greece in association with radioactive fallout from Chernobyl (Petridou et al., 
1996). In addition, X-ray examinations of pregnant women may be associated 
with increased risk of subsequent childhood ALL [for review, see (Doll and 
Wakeford, 1997)]. 
Certain cytostatic compounds, like alkylating agents and inhibitors of DNA 
topoisomerase II enzyme, increase the risk of leukaemia both in children and 
adults (Rubin et al., 1991; Felix et al., 1995). These treatment-related diseases 
occur mostly as AML, in some cases also as ALL [reviewed in (Greaves, 
1997)]. Alkylating agents damage DNA causing point mutations, chromosome 
breakages, translocations and loss of chromosomal material, especially losses of 
chromosomes 5 and 7 or their q-arms in AML [reviewed in (Pedersen-Bjergaard 
and Rowley, 1994)]. The topoisomerase II inhibitors lead to DNA breaks, 
deletions and translocations, the most common of which are translocations of 
the 11q23 region creating the MLL (mixed lineage leukaemia) gene fusions  
[reviewed in (Rowley, 1998)].  
According to preliminary studies, topoisomerase II inhibitors in mother’s 
nourishment or medicine during the pregnancy may cause leukaemia in infants 
(Ross, 1998). Infant leukaemia has also been linked to maternal alcohol intake, 
marijuana smoking, prior foetal loss, and parental exposure to pesticides and 
carcinogens [(Greaves, 1997) and references therein]. Finally, high weight at 
birth has also been associated with increased risk of childhood acute leukaemia 
(Yeazel et al., 1997).  
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5. Genetic aberrations in childhood acute 
leukaemias 
Present diagnostic methods reveal genetic aberrations in about 90% of ALL and 
AML patients. In most cases an aberration, which has been found at the time of 
diagnosis, is tightly connected with a specific leukaemia type and often also 
with some of its immunological or morphological subtypes (Heim and 
Mitelman, 1995). Especially in ALL, the distribution of the abnormalities is 
clearly different in children and adults. In addition, the distributions in infants 
and older children differ remarkably from each other (Figure 1) [reviewed in 
(Ma et al., 1999)]. The differences in frequencies offer a partial explanation to 
the different outcomes in different age groups.  
 
Figure 1. Prevalence of genetic changes in ALL with respect to different age 
groups (Ma et al., 1999). 
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5.1. Translocations 
The most common genetic alterations in leukaemias are translocations. These 
translocations create a rearrangement of genes, which leads a so-called proto-
oncogene to transform into an oncogene. The oncogene causes leukaemia either 
by stimulating cell division or by inhibiting the programmed cell death called 
apoptosis. Most of the proto-oncogenes involved in leukaemia encode 
transcription factors, many of which have revealed to be important regulators of 
the proliferation, differentiation and survival of blood cell precursors [reviewed 
in (Look, 1997; Biondi and Masera, 1998)]. The most frequent translocations of 
childhood ALL and AML are presented in Table 1. 
A translocation can activate a proto-oncogene by two different mechanisms. 
A more frequent event is a merger of two genes to form a fusion gene that 
produces abnormal chimaeric protein inducing leukaemia. As an example, 
translocation t(1;19) in ALL creates the fusion of E2A (immunoglobulin 
enhancer binding factors E12/E47) and PBX1 (pre-B-cell leukaemia 
transcription factor 1) genes. In the E2A-PBX1 fusion protein transactivating 
domains of E2A are joined to the DNA-binding domain of PBX1, which alters 
the transcriptional properties of the PBX1 transcription factor (Kamps et al., 
1990; Nourse et al., 1990; Van Dijk et al., 1993; LeBrun and Cleary, 1994; Lu 
et al., 1994). Another example is t(12;21), the most common translocation in 
ALL, which is discussed in more detail in Chapter 5.1.1. 
Another mechanism by which a translocation causes leukaemia is transfer of 
a normally ”quiet” transcription factor gene to the neighbourhood of active 
promoter or enhancer elements, which accelerate the function of the gene. For 
example, in translocations t(8;14), t(2;8) and t(8;22) in Burkitt leukaemia, the 
gene encoding the MYC transcription factor is exposed to the enhancer 
elements of an immunoglobulin gene. These enhancer elements cause over-
expression of the MYC gene, which is important in the regulation of cell 
division and cell death [reviewed in (Knudson, 2000)]. Immunoglobulin and T-
cell receptor genes are normally rearranged during B-cell and T-cell 
development to generate the enormous variety of immunoglobulins and 
receptors necessary for immunity. This explains the high frequency of these 
genes in the translocations of lymphoid malignancies. 
Besides transcription factors, also tyrosine kinases can be activated in the 
translocations of leukaemias. Tyrosine kinases are growth factor receptors or 
transmitters of signals inside the cell. For example, translocation t(9;22) that 
produces the well-known Philadelphia-chromosome, joins sequences of the 
BCR gene encoding a phosphoprotein with sequences of the ABL1 gene (v-abl 
Abelson murine leukaemia viral oncogene homolog 1) encoding a tyrosine 
kinase (Clark et al., 1987; Fainstein et al., 1987; Hermans et al., 1987). The 
BCR-ABL1 protein produced by the fusion gene has higher tyrosine kinase 
activity than normal ABL1 protein, and drives cell proliferation independently 
of growth factors required normally (Lugo et al., 1990). Translocation t(9;22) is 
found in 4% of childhood ALL, 25% of adult ALL and 95% of CML [reviewed 
in (Friedmann and Weinstein, 2000)]. In ALL, the breakpoint of the BCR gene 
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Table 1. The most frequent translocations in childhood ALL and AML (modified 
from Ma et al., 1999). 
 
 Abnormality Activated gene Mechanism of 
activation 
Type of 
protein 
Frequency 
(%) 
Cell type / 
Phenotype 
t(12;21)(p13;q22) TEL-AML1 Gene fusion TF 25 Precursor B 
t(9;22)(q34;q11) BCR-ABL1 Gene fusion TK 4 Precursor B 
t(1;19)(q23;p13) E2A-PBX1 Gene fusion TF 5 Precursor B 
t(17;19)(q22;p13) E2A-HLF Gene fusion TF <1 Precursor B 
t(4;11)(q21;q23) MLL-MLLT2 Gene fusion TF 3 Precursor B 
t(11;19)(q23;p13.3) MLL-MLLT1 Gene fusion TF <1 Precursor B 
t(8;14)(q24;q32) MYC Relocation to IgH TF 2-5 Immature B 
t(8;22)(q24;q11) MYC Relocation to IgL TF <1 Immature B 
t(2;8)(p12;q24) MYC Relocation to IgK TF <1 Immature B 
t(1;14)(p32;q11) TAL1 Relocation to TCRδ TF <1 T 
t(1;7)(p32;q34) TAL1 Relocation to TCRβ TF <1 T 
t(1;7)(p34;q34) LCK Relocation to TCRβ TK <1 T 
t(7;9)(q34;q32) TAL2 Relocation to TCRβ TF <1 T 
t(7;9)(q34;q34) NOTCH1 Relocation to TCRβ TF <1 T 
t(8;14)(q24;q11) MYC Relocation to TCRα/δ TF <1 T 
t(11;14)(p15;q11) LMO1 Relocation to TCRδ TF <1 T 
t(11;14)(p13;q11) LMO2 Relocation to TCRδ TF <1 T 
t(7;10)(q34;q24) HOX11 Relocation to TCRβ TF <1 T 
t(7;11)(q34;p13) LMO2 Relocation to TCRβ TF <1 T 
t(7;19)(q34;p13) LYL1 Relocation to TCRβ TF <1 T 
ALL 
t(10;14)(q24;q11) HOX11 Relocation to TCRδ  TF <1 T 
t(8;21)(q22;q22) AML1-ETO Gene fusion TF 12 AML-M2 
inv(16)(p13;q22) CBFB-MYH11 Gene fusion TF 12 AML-M4Eo 
t(3;21)(q26;q22) AML1-EV11 Gene fusion TF 1-2 AML 
t(3;5)(q25;q35) NPM-MLF1 Gene fusion ? 1 AML 
t(6;9)(p23;q34) DEK-CAN Gene fusion TF 2 AML-M2Baso 
t(9;11)(p21;q23) MLL-MLLT3 Gene fusion TF 5 AML-M5 
AML 
t(8;16)(p11;q13) MOZ-CBP Gene fusion TF <1 AML-M4/5 
Ig, immunoglobulin gene locus; TCR, T cell receptor gene locus; TF, transcription factor; TK, tyrosine kinase 
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differs from that in CML (Clark et al., 1987; Fainstein et al., 1987; Hermans et 
al., 1987). 
In addition to transcription factors and tyrosine kinases, other possible 
oncogenic proteins are, for example, growth factors and anti-apoptotic BCL2-
family proteins. They, however, seem to have a minor role in acute leukaemias. 
Many cytogenetic aberrations are prognostically significant and they are 
important factors when planning the treatment of a patient [for review, see (Ma 
et al., 1999; Friedmann and Weinstein, 2000; Pui, 2000)]. In childhood ALL, 
translocation t(9;22) is associated with poor prognosis (Uckun et al., 1998a; 
Forestier et al., 2000). Also  t(4;11) and other 11q23 translocations are adverse 
risk factors, and the unfavourable outcome seen in infant leukaemias is mostly 
attributable to high frequency of these translocations (Chen et al., 1993; 
Heerema et al., 1994; Pui et al., 1994; Rubnitz et al., 1994; Forestier et al., 
2000). Translocation t(1;19) has lost part of its prognostic significance along 
with intensification of the treatment (Raimondi et al., 1990), but it is still 
regarded as a marker of poor prognosis in some treatment protocols (Pui et al., 
2000). The patients with unbalanced der(19)t(1;19) seem to have better outcome 
than the patients with balanced t(1;19) (Forestier et al., 2000), and according to 
one report only the balanced form indicates inferior prognosis (Uckun et al., 
1998b). Translocation t(12;21) in ALL is generally regarded as a favourable 
prognostic sign (Liang et al., 1996; McLean et al., 1996; Borkhardt et al., 1997; 
Rubnitz et al., 1997b; Rubnitz et al., 1997c; Loh et al., 1998; Maloney et al., 
1999a; Rubnitz et al., 1999a). Translocations t(8;14), t(2;8) and t(8;22) are 
connected to Burkitt leukaemia, in which the prognosis is poor (Jaffe et al., 
2001). The three most common aberrations of AML, t(8;21), inversion(16) and 
t(15;17) are all signs of low risk (Grimwade et al., 1998). 
Translocations are also utilised in the search for minimal residual disease by 
fluorescence in situ hybridisation (FISH) and polymerase chain reaction (PCR) 
(see Chapters 6.2 and 6.3) (Campana and Pui, 1995; El-Rifai et al., 1997c). 
Minimal residual disease means the existence of a number of malignant cells 
while the patient is in remission according to conventional criteria. In many 
ALL and AML cases, residual disease is known to presage relapse, both during 
treatment and after it. Although further studies are needed to understand the 
significance of residual disease and the methods used in its monitoring are still 
being developed, it is believed to become one of the most important elements in 
the design of individual treatment in acute leukaemias. 
Finally, the understanding of the molecular mechanism of the translocation 
may in some cases lead into development of a specific form of therapy. This is 
shown by the rearrangement of the retinoic acid receptor alpha gene (RARα) in 
translocation t(15;17) typical for acute promyelocytic leukaemia (APL), and the 
successful treatment of APL with all-trans retinoic acid [(Melnick and Licht, 
1999) and references therein]. Furthermore, the treatment of the t(9;22)-positive 
patients with a specific inhibitor of the BCR-ABL1 tyrosine kinase has yielded 
promising results in CML and adult ALL (Druker et al., 2001a,b). The aim in 
the future is to clarify the complicated network effects of the proteins 
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transformed by translocations, which would further provide basis for the 
discovery of new effective drugs. 
5.1.1. Translocation t(12;21)(p13;q22) and the TEL and AML1 
genes 
The t(12;21)(p13;q22), the most common translocation of childhood ALL, is 
present in about 25% of the patients (Golub et al., 1995; Romana et al., 1995a; 
Romana et al., 1995b; Shurtleff et al., 1995; Liang et al., 1996; McLean et al., 
1996; Borkhardt et al., 1997). In adults, it is seen only in 2-3% of the cases 
(Aguiar et al., 1996; Kwong and Wong, 1997). Translocation t(12;21) occurs 
only in the B-precursor type of ALL (Romana et al., 1995b; Shurtleff et al., 
1995; Liang et al., 1996; McLean et al., 1996; Borkhardt et al., 1997; Raimondi 
et al., 1997; Rubnitz et al., 1997a). The translocation fuses the TEL gene 
located in 12p13 and the AML1 gene located in 21q22 (Golub et al., 1995; 
Romana et al., 1995a). For review about the TEL-AML1 fusion, see (Friedman, 
1999; Rubnitz et al., 1999b). 
TEL (translocation-ets-leukaemia; ETV6) encodes a sequence-specific 
transcriptional repressor, which belongs to ETS family of transcription factors 
(Golub et al., 1994; Fears et al., 1997; Fenrick et al., 1999; Lopez et al., 1999). 
The TEL protein contains an aminoterminal helix-loop-helix (HLH) domain 
and a carboxyterminal DNA-binding domain (Jousset et al., 1997; Poirel et al., 
1997). The HLH domain is responsible for forming protein homodimers with 
itself as well as heterodimers with FLI1 (friend leukaemia virus integration 1), 
another ETS factor (McLean et al., 1996; Jousset et al., 1997; Kwiatkowski et 
al., 1998). Studies of chimaeric mice with TEL-deficient cells have shown that 
TEL is critical for the normal transition of haematopoiesis from foetal liver to 
bone marrow (Wang et al., 1998). TEL is also involved in several other 
leukaemic translocations that generate fusion proteins [for review, see (Rubnitz 
et al., 1999b)]. The gene was first identified in t(5;12), present in CML, fusing 
TEL with the PDGFRB gene (platelet derived growth factor receptor, beta) 
(Golub et al., 1994). In the fusion protein the HLH domain of TEL joins to the 
PDGFRB transmembrane and tyrosine kinase domains resulting in constitutive 
activation of the PDGFRB kinase (Golub et al., 1994; Jousset et al., 1997). 
The AML1 gene (acute myeloid leukaemia-1; RUNX1) encodes a variety of 
transcripts giving rise to different proteins, which function as transcription 
factors [(Miyoshi et al., 1995; Levanon et al., 2001), for review about AML1, 
see (Lo Coco et al., 1997; Speck et al., 1999; Lutterbach and Hiebert, 2000; 
Downing, 2001)]. The major transcriptionally active protein isoform, AML1B, 
consists of an aminoterminal DNA-binding domain, also called the Runt 
domain, and a carboxyterminal transactivation domain (Meyers et al., 1995).  
Besides DNA binding, the Runt domain is responsible for heterodimerization of 
the protein with CBFB (core binding factor, beta subunit), which enhances the 
DNA binding and transactivation of AML1 (Meyers et al., 1993; Ogawa et al., 
1993; Wang et al., 1993). AML1 regulates transcription in a sequence-specific 
manner, acting mostly as a transcriptional activator but in some cases also as a 
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repressor (Meyers et al., 1993; Lutterbach and Hiebert, 2000 and references 
therein). It is known to activate a number of genes important in haematopoietic 
cell development, function and differentiation [(Lutterbach and Hiebert, 2000) 
and references therein]. Some of the lineage-restricted genes encode interleukin-
3, granulocyte-macrophage colony-stimulating factor, receptor for CSF1 
(colony stimulating factor 1), myeloperoxidase and subunits of the T-cell and 
B-cell antigen receptors. However, AML1 is apparently not capable of 
activating transcription alone, but it has been suggested to function as an 
organising factor that recruits lineage-specific elements to form transcriptional 
activation complexes that stimulate lineage-restricted transcription.  
AML1 is one of the most frequently rearranged genes in leukaemias. The 
translocations involving AML1 create gene fusions retaining the region 
encoding its DNA-binding domain [reviewed in (Speck et al., 1999)]. In 
addition to t(12;21), AML1 participates in t(8;21), the most common 
translocation of AML, which fuses AML1 to the ETO gene (eight-twenty-one) 
(Miyoshi et al., 1991). The function of AML1 is indirectly disrupted by 
inversion inv(16), another common rearrangement in AML. The inversion leads 
into the fusion of CBFB, the gene encoding the cofactor of AML1, with MYH11 
(myosin, heavy polypeptide 11, smooth muscle) (Liu et al., 1993). 
In the TEL-AML1 fusion protein formed by t(12;21), the HLH domain of 
TEL joins to the full-length AML1 protein (Golub et al., 1995; Romana et al., 
1995a). The transcription of the fusion gene is regulated by the promoter of 
TEL. The TEL-AML1 protein is a transcriptional repressor, which dominantly 
blocks the AML1-dependent transactivation. Repression by TEL-AML1 is an 
active process, in which the HLH domain of the fusion protein associates with 
co-repressors and a histone deacetylase protein (Hiebert et al., 1996; Fenrick et 
al., 1999; Hiebert et al., 2001). The histone deacetylase activity is thought to 
mediate the function of co-repressor complexes [(Lutterbach and Hiebert, 2000) 
and references therein]. The fusion of the HLH domain of TEL to AML1 thus 
transforms AML1 from a regulated to an unregulated transcriptional repressor 
(Hiebert et al., 2001). 
The TEL-AML protein is able to form heterodimers with the normal TEL 
through the HLH domains, which makes it possible that the fusion also alters 
the normal function of TEL (McLean et al., 1996). Interestingly, the non-
translocated allele of TEL is deleted in about 75% of the patients with t(12;21) 
(Cavé et al., 1997). The deletion seems to be a secondary event in the TEL-
AML1-positive ALL (Raynaud et al., 1996; Romana et al., 1996; Cavé et al., 
1997). One hypothesis for the role of this deletion is that the normal TEL 
interferes with the function of TEL-AML1 by heterodimerization (McLean et 
al., 1996). Another possibility is that the loss of TEL itself contributes to the 
development or progression of leukaemia (Friedman, 1999). 
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5.2. Numerical chromosome aberrations 
In addition to translocations, altered chromosome numbers are frequently found 
in leukaemias. In AML, losses or gains of single chromosomes (monosomies 
and trisomies) are common, whereas more radical changes are frequent in ALL 
(Heim and Mitelman, 1995). Especially hyperdiploidy (chromosome number 
>46) is common in childhood ALL. The number of chromosomes varies 
between 47 and 50 in about 15% and is more than 50 in about 27% of the cases. 
Hypodiploidy (chromosome number <46) is found in about 7% of the patients 
[reviewed in (Ma et al., 1999)].  
The numerical chromosome changes are frequent secondary aberrations, 
emerged during the progression of leukaemia. Therefore, the change in the 
chromosome number is often thought to represent a secondary aberration, even 
when it is the only detectable alteration. Were the changes of chromosome 
number primary or secondary, their significance for the development or 
progression of leukaemia is supported by the non-randomness of the 
chromosomes involved. In AML, for example, the monosomy of chromosome 7 
and trisomies of chromosomes 8 and 21 are frequent, and the gains of 
chromosomes 4, 6, 10, 21 and X appear often in hyperdiploid ALL (Heim and 
Mitelman, 1995).  
In ALL, hyperdiploidy in excess of 50 chromosomes indicates favourable 
prognosis, whereas hypodiploidy is a sign of poor prognosis (Chessels et al., 
1997; Forestier et al., 2000). Hyperdiploidy is also associated with low WBC 
[(Pui and Evans, 1998) and references therein]. The better outcome of patients 
with hyperdiploidy can result from higher accumulation of active metabolised 
form of methotrexate, which is one of the most widely used drugs in childhood 
ALL (Whitehead et al., 1990; Synold et al., 1994). 
5.3. Gene amplifications 
In addition to chromosomal translocations, an amplification can active a proto-
oncogene to produce an excess number of proteins encoded by the gene. Gene 
amplification is a frequent event in some solid tumours and lymphomas (Monni 
et al., 1997; Schwab, 1999 and references therein).  
In conventional cytogenetics (see Chapter 6.1) amplified chromosomal 
regions can be seen as intrachromosomal homogenously staining regions (HSR) 
or small extrachromosomal double minute chromosomes. There is only one 
report of double minute chromosomes in childhood ALL (Murray et al., 1998). 
In adult AML, double minute chromosomes are found in about 1% of the cases 
(Tanaka et al., 1993), usually involving the amplification of the MYC or the 
MLL gene (Alitalo et al., 1985; Asker et al., 1988; Tanaka et al., 1993; Park et 
al., 2000; Streubel et al., 2000; Andersen et al., 2001). 
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5.4. Tumour suppressor genes and allelic losses 
Another event that may initiate leukaemia is inactivation of a tumour suppressor 
gene. Tumour suppressor genes are essential for normal cell development and 
they prevent carcinogenesis. Usually the prerequisite of malignant 
transformation is inactivation of both alleles. Non-functioning first allele may 
be inherited. The activity may be neutralised by deletion, by hypermethylation 
of the promoter region or by point mutation. Very few tumour suppressor genes 
have been reported in acute leukaemias.  
Screening for chromosomal regions with loss of heterozygosity (LOH) is one 
way to track novel tumour suppressor genes. In childhood ALL, the regions that 
most frequently show LOH are the short arms of chromosomes 9 and 12 (in 
about 30-40% and 25-30% of the patients, respectively) (Takeuchi et al., 1995; 
Baccichet et al., 1997; Chambon-Pautas et al., 1998). 
The short arm of chromosome 9 contains two adjacently located and highly 
homologous tumour suppressor genes, CDKN2A (p16) and CDKN2B (p15) 
(9p21). These genes encode cyclin-dependent kinase inhibitors, proteins that 
negatively regulate cell cycle progression. CDKN2A and CDKN2B are 
frequently inactivated in many tumour types. Both of the genes are deleted, 
often concordantly, in almost 40% of childhood ALL [reviewed in (Drexler, 
1998)]. Furthermore, CDKN2B is inactivated by hypermethylation in about 
40% of childhood ALL and 50% of childhood AML, and CDKN2A in 40% of 
childhood AML [(Drexler, 1998) and references therein; (Guo et al., 2000)]. 
According to two studies, deletions of CDKN2A and CDKN2B, and 
hypermethylation of CDKN2B are frequently acquired during the time between 
diagnosis and relapse in childhood ALL, which suggests that the inactivation of 
these genes may be associated with the progression of the disease (Maloney et 
al., 1999b; Carter et al., 2001). The prognostic value of CDKN2A and CDKN2B 
inactivation is controversial [(Graf Einsiedel et al., 2001; Drexler, 1998) and 
references therein]. Recently, CDKN2A protein expression was reported to be 
an independent prognostic factor in childhood ALL (Dalle et al., 2002). 
However, as pointed by the authors, the CDKN2A expression can be altered not 
only by gene deletion and methylation, but also by other, unknown mechanisms. 
The region with frequent deletions in the short arm of chromosome 12 
(12p12-p13) contains the TEL gene, the counterpart of translocation t(12;21), 
and the CDKN1B gene. As mentioned previously, the non-translocated allele of 
TEL is deleted in most of the patients with t(12;21) (Raynaud et al., 1996; Cavé 
et al., 1997). However, homozygous deletions of TEL or mutations in the other 
TEL allele in the presence of hemizygous deletion are very rare, which suggests 
that it is not a classical tumour suppressor gene (Sato et al., 1995; Stegmaier et 
al., 1996). Hemizygous deletion of CDKN1B (cyclin-dependent kinase inhibitor 
1B; KIP1; p27) (12p12) has also been found to be a common feature in ALL by 
LOH and FISH studies (Pietenpol et al., 1995; Takeuchi et al., 1995; Komuro et 
al., 1999). The expression of CDKN1B is frequently reduced in several tumour 
types, and its under-expression in most of them is associated with poor 
prognosis. In contrast to most tumour suppressor genes, CDKN1B is 
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haploinsufficient for tumour suppression, which means that the absolute level of 
CDKN1B expression is critical for the tumour development [reviewed in 
(Philipp-Staheli et al., 2001)]. Deletion of only one allele of CDKN1B may thus 
be sufficient to cause a malignant effect.  
6. Genetic methods used in the diagnosis and 
follow-up of leukaemia 
6.1. Conventional cytogenetics 
Conventional cytogenetics has been used in the diagnosis of leukaemia since 
1970’s. It is based on the recognition of metaphasic chromosomes according to 
their specific banding patterns. The most widely used cytogenetic staining is 
Giemsa- or G-banding. Standard cytogenetics is still an important routine 
method at the diagnostic stage of leukaemia, giving an overview of genetic 
alterations in malignant cells. The method has, however, several weaknesses. 
The lack of metaphases may be a problem because the leukaemic cells, 
especially the blasts of childhood ALL, often fail to proliferate in the cell 
culture.  It is also possible that the normal cells from the patient sample divide 
as well or even more actively than the malignant cells, which may lead into the 
analysis of irrelevant cells. Other drawbacks of cytogenetics are that the quality 
is often insufficient for detailed analysis or that the aberration is too complex to 
be interpreted. Furthermore, many important chromosomal alterations are 
missed. For example the translocation t(12;21) of ALL cannot be detected by 
the method because the aberration does not change the banding pattern or the 
size of the chromosomes involved. Finally, conventional cytogenetics is 
laborious and time-consuming, and only about twenty cells can be analysed per 
patient. This is also the reason why the method cannot be used for the detection 
of minimal residual disease in patient follow-up. In recent years, several other 
techniques have been developed to compensate for the shortcomings of the 
banding technique. 
6.2. Molecular genetic methods 
A specific gene fusion caused by a translocation can be detected by Southern 
blotting and polymerase chain reaction (PCR). In Southern blotting, DNA is cut 
by sequence-specific restriction enzymes and the resulting fragments are 
separated in gel electrophoresis. The size of the fragment recognized by a gene-
specific probe is different in the fusion gene as compared to the fragment in the 
normal gene. The weaknesses of the method are that it is slow and that it 
requires large amount of cells. 
In most translocations the variance in cleavage sites is so great that PCR 
cannot be performed on DNA. RNA is therefore the usual source of PCR to 
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detect gene arrangements. First RNA has to be transformed into more stable 
complementary DNA (cDNA) by reverse-transcriptase (RT) enzyme and, 
accordingly, this type of PCR is called RT-PCR. Two specific primers, one for 
each side of the fusion point are needed for the reaction. No PCR product is 
detected in samples without a gene fusion, whereas cDNA is amplified 
exponentially in samples that contain the fusion.  
Southern blotting and RT-PCR are used as a support for diagnostics based on 
the result of G-banding analysis. Because specific probes or primers are 
required, the methods can be routinely used only for the most well-defined 
leukaemia-specific translocations, such as t(12;21), t(9;22), t(1;19) and t(4;11) 
in ALL. 
RT-PCR is also widely used to monitor minimal residual disease. PCR is 
highly sensitive: the method reveals one leukaemic cell among 10 000-100 000 
normal cells. Except for leukaemia-specific gene fusions, the normal 
rearrangements of immunoglobulin and T-cell receptor genes can be utilised in 
the disease follow-up, when the PCR targets can be identified in 95% of the 
patients (Campana and Pui, 1995; van Dongen et al., 1998). The rearrangement 
is unique in each cell and it can thus be used to find a monoclonal cell 
population. When PCR is performed on DNA, several primer pairs are needed 
for the detection of the immunoglobulin or T-cell receptor gene rearrangement. 
The detection of the rearrangement from RNA requires that specific primers are 
designed for each patient. The task is laborious and interpretation of the results 
is often difficult. 
In conventional PCR, contamination can be a recurrent problem. In addition, 
the method is not quantitative, which makes it deficient especially in residual 
disease monitoring. These drawbacks are overcome in quantitative real-time 
PCR, performed in a closed system, in which a fluorescent signal is generated 
and detected continuously during the amplification. The extent of fluorescence 
is directly proportional to the extent of PCR product. Real-time PCR has 
already been reported to be applicable to the quantification of residual disease 
in childhood ALL (Donovan et al., 2000; Eckert et al., 2000; Drunat et al., 
2001). Primer sets for childhood ALL are now commercially available and 
several laboratories are currently using the method in routine clinical studies of 
the disease. 
6.3. Molecular cytogenetic methods 
Molecular cytogenetics refers to the study of DNA or genes at chromosome- or 
cell-level. It is based on in situ hybridisation (ISH), in which a DNA probe 
binds with a specific region in the genome of the cell. The detection is based 
either on a colour produced by enzymatic reaction or on fluorescence, the latter 
being more widely used. In fluorescence in situ hybridisation (FISH), the probe 
is labelled with fluorochrome and the detection is performed using fluorescence 
microscope with specific filters [for detailed information about in situ 
hybridisation, see (Andreeff and Pinkel, 1999)]. 
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6.3.1. Chromosome painting and multicolour-FISH 
In chromosome painting, the whole chromosome or a chromosome arm is 
stained. The analysis is made from metaphase cells. The whole chromosome-
painting probe is a mixture of fragments from the entire length of a specific 
chromosome. Painting probes can be derived from chromosome-specific 
libraries, by PCR amplification from chromosome fractions or from 
microdissected DNA specific for each chromosome. Chromosome painting is 
used to verify and define translocations or numerical aberrations seen in G-
banding. However, the ability of chromosome painting to detect translocations 
like t(12;21) that are located near the telomeric regions of the chromosomes is 
limited [reviewed in (Kearney, 1999)]. Chromosome painting suits well for 
monitoring of minimal residual disease, although the sensitivity of the method 
is rather low (1:1000) compared to PCR (1:10 000-100 000) (El-Rifai et al., 
1997c). 
In multicolour-FISH alias 24-colour FISH the whole set of chromosomes is 
painted in a single hybridisation. Each chromosome is stained with a different 
combination of five fluorochromes. Using appropriate filters and software, all 
the chromosomes can be visualized in different artificial colours, each 
chromosome showing a specific colour. Multicolour-FISH is called multiplex 
FISH (M-FISH) (Speicher et al., 1996) or spectral karyotyping (SKY) (Schröck 
et al., 1996) depending on the technical details applied to fluorescence 
detection. Like the G-banding method, multicolour-FISH gives an overview of 
chromosomal changes in the whole of the genome. It is especially useful in 
defining complex translocations and so-called marker chromosomes with 
unknown origin, and it is used to support standard cytogenetics in diagnostics 
[reviewed in (Raap, 1998; Kearney, 1999; Patel et al., 2000)]. 
6.3.2. Interphase-FISH 
Centromere-specific and locus-specific probes provide fluorescent signals that 
can be analysed in interphase cells. Centromere-specific probes are targeted for 
highly-repetitive DNA present in the centromere of a chromosome. They are 
used for the detection of gains and losses of a specific whole chromosome. 
Specific gene fusions, gene deletions and gene amplifications can be studied 
with locus-specific probes. These probes are produced by cloning them in 
different kinds of vectors, such as cosmids, plasmids, phages, yeast artificial 
chromosomes (YACs) and bacterial artificial chromosomes (BACs). Locus-
specific probes are commercially available for several specific aberrations, e.g., 
the TEL-AML1 fusion of t(12;21). The locus-specific probe is usually a cocktail 
of two probes targetted for separate loci and labelled with different 
fluorochromes [reviewed in (Werner et al., 1997; Kearney, 1999)]. For 
example, in a cocktail that detects the TEL-AML1 fusion, the probe for the TEL 
gene is labelled with green fluorochrome and the probe for the AML1 gene with 
red fluorochrome. Thus the normal TEL allele produces a green signal and the 
normal AML1 allele a red signal. In the TEL-AML1 fusion green and red signals 
are fused producing yellow colouring. 
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The study of interphase cells has major advantages over the study of mitotic 
cells. As mentioned, especially the leukaemic blasts of ALL proliferate poorly 
in cell culture, and mitotic cells may not represent the neoplastic clone 
[reviewed in (Kearney, 1999)]. Another advantage of interphase FISH is that it 
can be combined with the study of the immunophenotype and morphology of 
the cell by immunocytochemical staining [reviewed in (Werner et al., 1997)]. 
This makes it possible to define the lineage and maturation stage of the cells 
with the aberration. Finally, interphase FISH can be used for stored material 
including smear preparations, which is beneficial especially in retrospective 
studies [reviewed in (Cuneo et al., 1997; Wolfe and Herrington, 1997)].  
Interphase-FISH can be used both in diagnostics and follow-up. However, 
the method shows a high number of false positive cells, which seriously limits 
its sensitivity for monitoring residual disease. For centromeric probes, the false-
positive rate varies from 0.5% (false trisomy) to 2% (false monosomy), and for 
locus-specific probes the rate ranges from 2% to 5% [reviewed in (Ma et al., 
1999)]. When searching for fusion genes, the problem can be reduced by using 
a series of probes spanning both translocation breakpoints, resulting in two 
fusion signals in the presence of the translocation. Another strategy is to use 
three or even four different colours. However, the more complex is the colour 
scheme, the more difficult is the analysis [reviewed in (Kearney, 1999)]. 
6.3.3. Comparative genomic hybridisation 
Comparative genomic hybridisation (CGH) (Kallioniemi et al., 1992) is a 
modification of FISH that allows screening of the whole genome for DNA 
sequence gains and losses in a single experiment [for review, see (Forozan et 
al., 1997; Raap, 1998; Tachdjian et al., 2000)]. The principle of the method is 
illustrated in Figure 2. DNA extracted from a patient sample is cut into small 
fragments and labelled with green fluorochrome using nick translation. 
Similarly, DNA extracted from normal tissue, usually blood, is cut and labelled, 
but red fluorochrome is used for labelling. Equal amounts of differently labelled 
patient DNA and normal DNA are mixed and hybridised into normal metaphase 
spreads (Figure 2). The patient DNA and normal DNA compete for the same 
target sequences, and the hybridisation takes place proportionally to the 
amounts of patient DNA and normal DNA present. Consequently, the over-
represented chromosomal regions in the patient are seen as green, and under-
represented as red. For a detailed and reliable analysis, images of the hybridised 
metaphases have to be captured by a CCD (charge coupled device) camera 
connected to a fluorescence microscope, and the intensities of red and green 
fluorescence are calculated using image analysis software. The software 
produces profiles of green-to-red fluorescence ratios along the entire length of 
each chromosome. The gains and amplifications of patient DNA can be 
detected as chromosomal regions with increased ratio, and the losses as regions 
with reduced ratio. 
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Figure 2. The principle of comparative genomic hybridisation (CGH). DNA 
extracted from patient sample is labelled with green fluorochrome and DNA 
from normal blood with red fluorochrome. Equal amounts of differently 
labelled patient and normal DNAs are mixed and hybridised into normal 
metaphase chromosomes. Images of the hybridised metaphases are captured 
using fluorescence microscope and CCD camera. The profiles of greed-to-red 
ratio are calculated along each chromosome using image analysis software. 
When the ratio exceeds or falls below certain limits, the region is considered 
gained or lost in the patient sample, respectively. 
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CGH is used in clinical diagnostics to supplement conventional cytogenetics. In 
addition, the method has many applications in cancer research and it has 
provided an enormous amount of data since it was first introduced in 1992 
[(Kallioniemi et al., 1992); for review, see (Knuutila et al., 1998, 1999)]. By 
revealing chromosomal regions that are recurrently gained or lost, CGH is 
valuable for example in pinpointing regions with putative oncogenes or tumour 
suppressor genes.  
A remarkable advantage of CGH is that no intact cells or metaphases from 
the patient are required. Moreover, only a small amount of sample (less than 
1 µg DNA) is needed. DNA from even a few cells is enough for the method, if 
it is first amplified by PCR [reviewed in (Forozan et al., 1997)]. This procedure 
is applicable in research, but it is too labour-intensive in routine diagnostics. 
Patient DNA can be obtained from fresh, frozen or paraffin-embedded tissue. 
The disadvantage of CGH is its inability to reveal balanced translocations 
and inversions because they do not cause alterations in DNA copy number. 
Another limitation is that an abnormality can be detected only when it is present 
in at least 50% of the cells (Kallioniemi et al., 1994). Thus, subclones with 
aberrations developed by clonal evolution may be missed by the method. 
The reliance on metaphase chromosomes as hybridisation targets reduces the 
value of CGH findings due to resolution limitations. The minimum size of gains 
and deletions that can be detected is considered to be about 10 Mb 
(megabasepairs). For a region with high-level amplification, the sensitivity is 
higher: for example, a 5-10 fold amplification of 1 Mb is detectable [reviewed 
in (Forozan et al., 1997; Tachdjian et al., 2000)]. It has also been stated that a 
deletion of 3 Mb can be easily detected (Kirchhoff et al., 1999).  
The resolution of CGH technique can be substantially increased by replacing 
the condensed metaphase chromosomes with cloned genomic DNA, arrayed in 
small spots on a glass slide. The technique is called matrix-CGH or array-based 
CGH (Solinas-Toldo et al., 1997). So far, CGH arrays of specific chromosomal 
regions have been used mostly for research purposes, but also a study with a 
genome-wide CGH array has been reported (Pollack et al., 1999). Perhaps 
focussed disease-specific CGH arrays will be available for clinical diagnostics 
in the future. 
Review of the literature  
 31 
7. Gene expression pro filing by DNA arrays 
The sequencing of human genome has identified approximately 19 000 genes 
and tens of thousands partial fragments of genes termed expressed sequence 
tags (ESTs) (Alizadeh et al., 2001). At present, the number of human genes is 
estimated to be about 30 000–35 000 (Pennisi, 2000; Claverie, 2001). The 
availability of the sequences has made it possible to use novel techniques to 
study the function of genes as well as their role in diseases. The most powerful 
of these techniques is DNA array technology, first introduced in 1995, which 
has made it possible to study the expression of thousands genes in a single 
experiment [(Schena et al., 1995; Zhao et al., 1995; Schena et al., 1996), for 
review, see (Duggan et al., 1999; Marx, 2000; van Hal et al., 2000; Golub, 
2001; Maughan et al., 2001; Rozovskaia et al., 2001; Gershon, 2002; 
Ramaswamy and Golub, 2002)]. As vigorous development within the field has 
translated into decreasing performance costs, DNA array technology has 
become a widely used method to study gene expression in genomic scale. The 
method has already provided important insights into human neoplasms by 
identifying specific cancer subtypes as well as genes that are important for the 
development of various cancers.  
7.1. Types of array and principles of the method  
A DNA array contains PCR-amplified cDNAs or oligonucleotides spotted 
densely and systematically on solid surface, usually filter or glass. Each spot 
represents a single gene. The variety of commercially available arrays includes 
genes associated with cancer or with functional traits of a specific tissue. 
Another alternative is to use a custom-made array with a set of genes 
determined by the researcher. Today, also arrays covering genes of nearly the 
entire genome are available. 
Arrays can be either glass- or filter-based according to surface material. 
Moreover, two types of array exist according to the kinds of probe used in the 
gene spots. cDNA arrays, alias spotted arrays, are made by mechanical 
deposition of solutions containing PCR-amplified cDNA fragments in small 
spots on filter or glass. The oligonucleotide arrays are made by deposition or 
more often by direct synthesis of oligonucleotides on a glass slide. 
In the nylon and plastic filter-based cDNA array method, the cDNA derived 
from mRNA is radioactively labelled and the labelled patient and reference 
cDNAs are hybridised to separate filters. The principle of the filter-based 
system is illustrated in Figure 3.  
Filter arrays were appreciated as a relatively economical alternative that can 
be assembled easily, often on an already existing basis. However, glass-based 
arrays are rapidly replacing filter arrays in gene expression studies. When using 
glass-based cDNA arrays, cDNA derived from mRNA is labelled fluorescently. 
Fluorochromes of different colours are used for cDNAs from test and reference 
samples, usually red for the test cDNA and green for the reference cDNA. The 
differently labelled test and reference cDNAs are simultaneously hybridised to 
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the same array slide in a competitive manner. The expression differences 
between the test and reference samples are then measured as the ratio of red-to-
green fluorescence in each spot [reviewed in (Duggan et al., 1999; Alizadeh et 
al., 2001)]. 
The glass-based cDNA arrays have several advantages over the membrane-
based arrays. Glass allows higher density of spots, which enables spotting of 
more than 50 000 genes on a single microscope slide [reviewed in (Alizadeh et 
al., 2001)]. The high-density arrays are called microarrays. Furthermore, the 
fluorescence-based procedure is faster, because of the long exposure time 
required for detection of radioactivity [reviewed in (Cox, 2001)]. A great 
advantage is also the avoidance of problems that arise from handling and 
storage of radioactive material. Finally, simultaneous hybridisation of distinctly 
labelled test and reference cDNAs intrinsically normalizes for noise and 
background in their comparison [reviewed in (Harrington et al., 2000)]. 
The spots in glass-based arrays can also be oligonucleotides instead of 
cDNAs (Fodor et al., 1993; Lipshutz et al., 1999). Oligonucleotides are short 
fragments that allow even higher density of spots than cDNAs. Because these 
short oligomers frequently cross-hybridise with several genes, the arrays 
contain several oligomers for the measurement of each gene [(reviewed in (Wu, 
2001)]. The most commonly used oligonucleotide arrays are GeneChips, 
manufactured by Affymetrix (Santa Clara, CA, USA). In the Affymetrix 
system, the experimental and reference mRNAs are enzymatically amplified, 
hybridised to separate arrays, and the detection is based on single colour 
fluorescent label. Oligoarrays offer higher specificity than cDNA arrays because 
the chances of cross-hybridisation can be minimised [reviewed in (Ramaswamy 
and Golub, 2002)]. In addition, smaller amount of total RNA (around 10 µg per 
sample per hybridisation) is needed than when using glass-based cDNA arrays 
(around 50 µg) (2 µg in filter-based system). Oligonucleotide arrays can also be 
used to monitor sequence polymorphisms and splice variants (DeRisi and Iyer, 
1999; Lipshutz et al., 1999). A particular advantage of Affymetrix GeneChips is 
the ability to recover samples from a chip after hybridisation (Ramaswamy and 
Golub, 2002). The disadvantages of oligoarrays compared to glass-based cDNA 
arrays are higher price and minor flexibility, and the requirement of a priori 
knowledge of the gene sequences.  
7.2. Problems concerning patient sample and 
reference 
The limitation of the glass-based DNA array technique, especially when using 
the cDNA system, is the large amount of RNA required. The number of cells in 
the bone marrow samples of leukaemia patients, especially children, is limited. 
Therefore the amount of RNA obtained from the samples is usually too small for 
the glass-based cDNA system. Techniques for amplifying mRNA prior to array 
hybridisation are, however, being improved to overcome this problem [reviewed in 
(Lockhart and Winzeler, 2000; Hughes and Shoemaker, 2001)]. High levels of 
roughly linear amplification have already been achieved (Luo et al., 1999). 
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Figure 3. Principle of gene expression profiling using filter-based cDNA 
arrays. mRNA is extracted from the patient sample and the normal reference. 
The mRNAs are converted into radioactively labelled cDNA by RT-PCR. The 
radioactively labelled patient cDNA and reference cDNA are hybridised to 
separate array filters. The hybridised filters are exposured to an imaging plate, 
which is scanned using phosphorimager. The intensities of corresponding gene 
spots in patient and reference images are compared using software to obtain 
the intensity differences between the patient and the reference (reviewed in 
Duggan et al., 1999; Cox, 2001). The intensity difference in each gene spot 
reflects the difference in the expression of the gene between the patient and the 
reference. 
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Most cancer specimens are a mixture of normal and malignant cells, which is a 
problem that must be taken into account in gene expression analyses. One 
approach to study only a specific cell type of bone marrow is the purification of 
cells of specific lineage and differentiation-stage with the help of monoclonal 
antibodies (Chen et al., 2001). This is, however, a laborious procedure whereby 
a large proportion of cells, and thus RNA, is often lost. Another possibility is 
“virtual purification” that has already been used in solid tumours (Ross et al., 
2000). This can be performed in a computer by clustering and identifying 
groups of genes whose expression can be attributed to the normal cells on the 
basis of cell-specificity [reviewed in (Alizadeh et al., 2001)]. 
Another problematic issue in gene expression studies is the choice of correct 
reference. When identifying genes with abnormal expression in a specific 
cancer type, the ideal reference sample would consist of the same types of 
normal cells in the same proportions as in cancer specimen. When using 
purified cancer cells, the normal cells of same cell type should be used as 
reference. In cancer classification, the same type of reference should be used for 
all the samples. The requirements for the reference are not as strict as filtering 
of abnormally regulated genes calls for, but an increase in the level of similarity 
between the reference and test samples leads to improved accuracy. 
7.3. Data analysis 
The study of hundreds to thousands of genes in a large series of patients 
produces a huge amount of data, which can be analysed only by using 
sophisticated software and statistical methods [for detailed information about of 
data analysis, see (Hand et al., 2001)]. Before statistical analysis, the data may 
need pre-processing. It is often necessary to correct or normalise the differences 
in the overall intensities between the arrays. The normalisation can be 
performed using housekeeping genes, which are genes that are expressed at the 
same level in all the samples studied, including the reference. Another 
possibility is to subtract the average of the intensities in one array from each 
intensity value, which standardises the average in all arrays to zero.  
So-called parametric tests, which usually offer the highest statistical power, 
require that data are normally distributed. Generally, gene expression data are 
approximated to normal distribution after logarithmic transformation. A 
logarithmic transformation is particularly useful when dealing with ratios of 
expression between test and reference samples. The problem with ratios is that 
over- and under-expression give values of different magnitude. For example, a 
two-fold over-expression will have more weight in any comparison than a one 
half under-expression. After logarithmic transformation the values will be of 
identical magnitude [reviewed in (Dopazo et al., 2001)]. 
The choice of a correct statistical method is important for the reliability of 
the results. Array data analysis is continuously developing. Several different 
statistical methods have been used to answer similar kinds of questions.  
The search of differentially expressed genes has mainly relied on hypothesis 
testing, which employs thresholding rules [reviewed in (Dopazo et al., 2001; 
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Wu, 2001)]. The disadvantage of these methods, however, is loss of 
information. Another alternative is to use principal component analysis (PCA), 
a technique that reduces the dimensionality of data. The genes are considered to 
be points in a multidimensional space with as many dimensions as samples 
measured. The aim of PCA is to get a two-dimensional projection of the points 
that conserve most of the information of the original data [reviewed in (Dopazo 
et al., 2001)]. These points, or scores, of each gene represent its expression 
difference between the experimental samples and the reference samples. When 
the genes are ranked according to their scores, the most over-expressed genes 
appear in one end of the list and the most under-expressed in the other.  
In cancer classification and gene-grouping studies, cluster analysis is usually 
employed [(reviewed in (Dopazo et al., 2001)]. Two types of cluster analysis 
exist: hierarchical and non-hierarchical clustering. Hierarchical clustering 
allows the detection of higher order relationships between clusters, whereas 
non-hierarchical clustering groups the expression profiles to a predefined 
number of clusters. The hierarchical clustering has been preferred in array 
studies. The most frequently used method is aggregative hierarchical clustering, 
which represents the data in the shape of binary tree, in which the most similar 
profiles are clustered in a hierarchy of nested subsets.  
7.4. Applications 
DNA array technology has several applications in cancer research [for review, 
see (Marx, 2000)]. First, it can be applied to searching for genes that are up-
regulated or down-regulated in a given cancer [for review, see (Wu, 2001)]. In 
this way, possible genes and proteins for drug targeting may be identified. 
Furthermore, the effect of drugs on gene expression can be studied, which in 
turn facilitates finding of markers for drug sensitivity and genes associated with 
drug resistance (Zembutsu et al., 2002).  The results may eventually lead to 
individualised treatment with more effective and less harmful drugs, as well as 
to development of new drugs.  
In addition to identifying single genes, novel biological pathways can be 
found by using DNA arrays. This helps us to understand the complex molecular 
processes in a given tissue and the biological roles of the genes with unknown 
functions [reviewed in (Lockhart and Winzeler, 2000; Maughan et al., 2001)]. 
Cancer expression profiling can lead to discovery of novel cancer subtypes 
as well as to identification of genes whose differential expression can be used in 
classification of cancer or as predictive markers of cancer behaviour [(Golub et 
al., 1999): for review, see (Alizadeh et al., 2001)]. The applicability of the DNA 
array method to cancer classification was first demonstrated by Golub et al. 
(1999) in ALL and AML patients. In the study, gene expression profiling was 
first performed on 38 patients (27 ALL, 11 AML) using Affymetrix 
oligonucleotide arrays with more than 6800 genes. The authors used an 
algorithm to select 50 genes whose expression level differed most between ALL 
and AML. The expression patterns of these genes reliably distinguished patients 
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with ALL from those with AML, both in the original group of 38 and also in 
another group of 36 patients not previously studied.  
Perhaps the most notable example of classification studies is the discovery of 
two distinct subtypes of diffuse large B-cell lymphoma (Alizadeh et al., 2000). 
When the expression profiles were compared, the subtypes were seen to express 
two distinct groups of genes, reflecting different stages of B-cell development. 
Moreover, these two groups appeared to have significantly different treatment 
responses. The microarray study provided a large set of candidate markers to 
distinguish the two subtypes, which will probably help to optimise the treatment 
of the patients in the future. 
DNA arrays can also be used to study the correlation of gene expression with 
known subgroups of cancer. Armstrong et al. used Affymetrix GeneChips with 
12 600 genes, and showed 17 patients with MLL rearrangements to have a 
characteristic, highly distinct gene expression profile when compared to 20 
patients with common childhood ALL or 20 patients with AML (Armstrong et 
al., 2002). For example, the homeobox (HOX) genes, important in 
haematopoiesis and regulated by MLL, were expressed at higher levels in the 
ALL patients with MLL fusions than in the patients with common ALL. Using 
cDNA arrays with about 9 700 genes, Rozovskaia et al. also found over-
expression of HOXA9 in 14 ALL patients with t(4;11) compared to 10 ALL 
patients with similar phenotype but without the translocation (Rozovskaia et al., 
2001). Recently, a comprehensive study was performed by Yeoh et al. on 360 
childhood ALL patients using Affymetrix chips with 12 600 genes (Yeoh et al., 
2002). The authors demonstrated distinct expression profiles in prognostically 
important ALL subtypes, including T-ALL, t(1;19), t(9;22), t(12;21), MLL 
rearrangement and hyperdiploidy >50 chromosomes. In addition, they identified 
another ALL subgroup based on its unique expression profile. Furthermore, 
they showed expression profiles to differ between the diagnostic samples of 
patients who relapse and those who remain in continuous complete remission. 
In the future, new molecular prognostic markers provided by arrays should 
be useful in diagnosis and in monitoring response to therapy. Less costly and 
simpler methods that are already in routine clinical use, such as real-time PCR, 
could be applied. Another conceivable possibility is to apply the DNA array 
method itself to clinical diagnostics, after commercially available, low-cost, 
technically simple arrays and easy-to-use software have become available 
(Ramaswamy et al 2002). Furthermore, identification of novel molecular targets 
associated with leukemogenesis is likely to lead into development of new 
efficient drugs with minimal side effects. 
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Aims of the study 
1. To screen DNA copy number changes in childhood acute leukaemias using 
comparative genomic hybridisation (CGH). 
 
2. To investigate the applicability of the CGH method to the diagnostics of 
childhood acute leukaemias. 
 
3.  To expand the characterization of certain genomic regions with recurrent 
amplification or frequent loss detected by CGH in childhood acute 
lymphoblastic leukaemia (ALL). 
 
4.  To perform expression profiling of genes related to the function of blood 
cells or their precursors in childhood ALL using cDNA arrays. 
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Material and methods 
1. Material 
1.1. Patients and samples 
All cytogenetic and molecular genetic analyses were performed from bone 
marrow specimens of children with AML (Study I) and with ALL (studies II-
V). The number of patients in each study is shown in Table 2.  Patients that 
were included in two or more studies are shown separately. 
 
Table 2.  Number of patients in the studies, the methods used, and the hospitals 
where the patients were treated.  
Type of 
leukemia 
Number of 
patients 
Studies Methods Hospital 
AML 19 I CGH, CC# HUCH, KUH 
67 II CGH, CC# HUCH 
99* III FISH HUCH, KUH, OUCH, 
TAUH, TUCH 
5** II, III, IV CGH, CC#, FISH HUCH 
4 III, IV FISH KUH 
13 V cDNA array,  
real-time RT-PCR 
HUCH 
ALL 
 
4 III, V FISH, cDNA array, 
real-time RT-PCR 
HUCH 
*, 87 smear preparations; **, smear preparations; #CC (conventional cytogenetics) was 
performed according to Knuutila et al. (1981). The karyotype data were retrieved from clinical 
records.; HUCH, Helsinki University Central Hospital; KUH, Kuopio University Hospital; 
OUCH, Oulu University Central Hospital; TAUH, Tampere University Hospital; TUCH, Turku 
University Central Hospital 
 
In Study I, frozen bone marrow specimens from 19 children with AML were 
investigated by CGH (Table I, Publication I). All the patients were studied at 
the diagnostic stage of the disease. The mean age of the patients was 8.5 years 
(range 1.0-15.6 years). In Study II, CGH was performed on frozen samples 
from 72 patients with ALL at the time of diagnosis (Table I, Publication II). The 
mean age of the patients was 6.5 years (range from two months to 15.7 years). 
In Study III, FISH was performed for 112 children with ALL, including three 
patients with high-level amplification at chromosome 21 shown by CGH. 
Ninety-two of the patients were studied retrospectively from smear preparations 
and 20 from cultured cells. All patients were studied at diagnosis except three, 
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who were studied at the time of relapse. The mean age was 6.2 years (range 0.2 -
14.9 years). 
Study IV focussed on nine ALL patients who had shown loss at 12p in CGH 
studies (Table IV, Publication IV). Cultured cells from four patients and smear 
preparations from five patients were analysed by FISH. All samples were 
obtained at diagnosis and the mean age of the patients was 6.5 (range 2.2-11.7). 
The overall and event-free survivals of the nine patients were compared with 
survival of 70 other patients with no loss at 12p in CGH. The mean age of the 
70 patients was 4.5 (range 0.6-15.7). 
In Study V, frozen bone marrow specimens from 17 ALL patients were 
investigated by the cDNA array technique (Table I, Publication V). All patients 
showed a common phenotype except one (Patient 8) who had a precursor-B 
disease. The samples were diluted 1:10 in RNA/DNA stabilisation reagent for 
blood and bone marrow (Boehringer Mannheim GmbH, Mannheim, Germany) 
for simultaneous cell lysis and stabilisation of the nucleic acids. Fourteen of the 
patients were studied at the time of diagnosis and three at relapse. The mean age 
was 5.0 years (range 1.2-12.7 years). 
Most of the samples were obtained from the Hospital for Children and 
Adolescents, Helsinki University Central Hospital. In studies II, III and IV, part 
of the samples was received from four other Finnish university hospitals (Table 
2). The patients were diagnosed and treated following the guidelines set by the 
Nordic Organization for Paediatric Haematology-Oncology (NOPHO) 
(Gustafsson et al., 1998). However, the majority of the patients who were 
studied retrospectively from the smear preparations were diagnosed and treated 
during 1975 to 1981 according to the conventional protocols of that time. 
1.2. References 
In CGH studies (I and II), peripheral blood from healthy donors was used as 
reference. Because of the very limited number of precursor-B cells in normal 
bone marrow, two pools of mature B cells from adenoid samples of healthy 
children were used as references in the cDNA array study (V). 
2. Methods 
2.1. Comparative genomic hybridisation (I and II)  
CGH was performed using direct fluorochrome-conjugated probes according to 
a protocol described by Kallioniemi et al. (1992, 1994) with minor 
modifications. DNA extracted from bone marrow samples of the patients was 
labelled green with fluorescein-isothiocyanate (FITC)-conjugated dCTP and 
dUTP (DuPont, Boston, MA, USA) by nick translation to obtain fragments 
ranging from 600 to 2000 base pairs as described by El-Rifai et al. (1997b). 
Similarly, the reference DNA extracted from normal peripheral blood was 
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labelled red with Texas-red-conjugated dCTP and dUTP (Du-Pont). Equal 
amounts (1 µg) of labelled patient and reference DNAs together with 20 µg of 
unlabelled Cot-1 DNA to block the binding of repetitive sequences (Gibco 
BRL, Life Technologies, Gaithersburg, MD, USA) were precipitated with 1/10 
volume of 3 M sodium acetate and 9 volumes of absolute ethanol at -20°C 
overnight. The DNAs were dissolved in 10 µl of hybridisation buffer [50% 
formamide/10% dextran sulphate/2xSSC (pH 7)] at 37°C for two hours. The 
slides with normal metaphase spreads were denatured in 50% 
formamide/2xSSC (pH 7) at 65°C for 2 minutes, followed by dehydratation in 
increasing alcohol series (3 minutes each, on ice). The hybridisation mixture 
was denatured at 75°C for 5 minutes and applied onto denatured slides. 
Hybridisation was performed in a moist chamber at 37°C for two days. After 
hybridisation the slides were washed three times in 50% formamide/2xSSC 
(pH 7), twice in 2xSSC, and once in 0.1xSSC at 45°C, followed by 2xSSC, PN 
buffer [0.1 M NaH2PO4/0.1 M Na2HPO4–0.1% NP-40 (pH 8)] and distilled 
water at room temperature for 10 minutes each. The slides were mounted with 
VectaShield-DAPI (Vectashield, Vector Laboratories, Burlingame, CA, USA), 
an antifading medium containing the counterstain (DAPI). 
The hybridisations were analysed using an Olympus fluorescence 
microscope and the ISIS digital image analysis system (MetaSystems GmbH, 
Altlussheim, Germany), which consists of an integrated high-sensitivity 
monochrome charge-coupled device (CCD) camera and automated CGH 
analysis software. Three-colour images of 8-12 metaphases with good 
morphology and strong even hybridisation were acquired from each sample. 
The chromosomes were recognized and arranged based on the banding pattern 
in the DAPI counterstaining. The green-to-red fluorescence intensity ratios were 
calculated along each of the chromosomes and visualised as ratio profiles. In the 
chromosomal areas with no copy number change, the ratio was approximately 
1. The chromosomal region was considered to be over-represented (gained) if 
the ratio exceeded 1.17 and under-represented (lost) if the ratio was below 0.85. 
A ratio in excess of 1.5 was interpreted as a high-level amplification. The cut-off 
levels were determined by experiments in which two differently labelled normal 
DNAs were hybridised to same metaphase spreads. The centromeric regions of 
chromosomes 1, 9 and 16, short arms of acrocentric chromosomes and whole 
chromosome Y were excluded from the analysis because they contain a large amount 
of heterochromatin. The results were confirmed by estimating the error probability and 
using 99% confidence intervals for the ratio profile.  
2.2. Fluorescence in situ hybridisation (III and IV) 
The FISH studies were performed using a commercial dual-colour probe 
cocktail with spectrum green-conjugated probe specific to the TEL gene and 
spectrum orange-conjugated probe specific to the AML1 gene (Vysis, Downers 
Growe, IL, USA). The hybridisations and washings were performed following 
the manufacturer’s instructions. Briefly, the slides were denatured in 70% 
formamide/2xSSC at 73°C for 5 minutes and the probe at 73°C for 5 minutes. 
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The probe was applied to the slide and hybridised at 37°C overnight. The slides 
were washed in 50% formamide/2xSSC (three times, 10 minutes each), 2xSSC 
(10 minutes) and 2xSSC/0.1% NP-40 (5 minutes) at 46°C. The slides were 
counterstained and mounted with VectaShield-DAPI (Vectashield). 
The smear preparations were pre-treated before FISH. First, the coverslips 
were removed by xylene and the slides were dehydrated in increasing alcohol 
series, followed by fixation in methanol/acetic acid (3:1) at 4°C overnight. Then 
the slides were treated in 1 M natriumthiocyanate for 10 minutes at 65°C and 
washed in 2xSSC for 5 minutes at room temperature. Next the slides were 
treated in 0.01 N HCl for 10 minutes and in 0.05 N HCl with pepsin 
(0.05 mg/ml) for 8 minutes at 37°C. Finally, the slides were washed under cold 
running tap water for 5 minutes and dehydrated in increasing alcohol series. 
The analysis was performed from three-colour images acquired using a 
fluorescence microscope and the ISIS digital image analysis system 
(MetaSystems) developed for CGH. Filters specific to FITC, Texas-Red and 
DAPI were used (Chroma Technology Corp., Brattleboro, VT, USA). In Study 
III, at least 50 interphase cells were analysed from the images of each sample. 
In addition, 20 metaphases were studied from the three samples with more than 
four copies of AML1 and from three of the samples with 3-4 copies. In Study 
IV, at least 30 interphases from the TEL-AML1 fusion positive samples and 50 
interphases from the fusion negative sample were analysed.  
-
free survivals (IV) 
The overall and event-free survivals of the nine patients with loss at 12p were 
compared to those of 70 patients who showed no change at 12p by CGH. The 
Kaplan-Meier method was used to analyse the outcome and standard errors (SE) 
were calculated according to Greenwood’s formula. The event-free survival was 
calculated from the date of diagnosis to the date of an adverse event or time of 
last contact. Relapse, death in remission, and second malignancy were 
considered as events. The survival of the patients without events was calculated 
from the date of diagnosis to the time of last contact or to the date of stem cell 
transplantation in the first complete remission. The log-rank test was employed 
to compare the outcome between the groups. The data were analysed with SPSS 
for Windows software (version 8.0.1.). 
2.3. Calculation and comparison of overall and event
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2.4. cDNA array method (V) 
2.4.1. cDNA array hybridisation 
Total RNA was extracted from patient and reference samples. First, nucleic 
acids were isolated using mRNA isolation kit (Boehringer Mannheim) 
according to the first steps in the manufacturer’s protocol. After this, the DNA 
was removed following Clontech’s (Palo Alto, CA, USA) instructions for 
DNase treatment of total RNA. The quality of the total RNA was checked by 
gel electrophoresis. 
The study was performed using AtlasTM Human Hematology/Immunology 
cDNA expression arrays (Clontech) with duplicate cDNA spots of 415 genes 
immobilised on a nylon membrane. The genes are known to be expressed in 
normal haematopoietic cells, haematopoietic cell lines or in haematological 
disorders. 
Total RNA (3-4 µg) was reverse-transcribed into 33P-labelled cDNA using 
the AtlasTM pure total RNA labelling system (Clontech) with gene-specific 
primers following the manufacturer’s instructions. The labelled cDNA probes 
were purified from unincorporated 33P-labelled nucleotides and small cDNA 
fragments by column chromatography.  
The cDNA probes were hybridised to the array according to the 
manufacturer’s instructions. Briefly, the array was first pre-hybridised with 
sheared salmon testes DNA in hybridisation buffer (ExpressHyb) for 30 
minutes at 68°C. The probe was denatured in denaturing solution at 68°C for 20 
minutes followed by pre-hybridisation with Cot-1 DNA in neutralisation 
solution at 68°C for 10 minutes. Next the probe was added to the pre-
hybridisation solution and hybridised with the array overnight at 68°C. The 
non-specifically bound probe was removed by washing the array three times in 
2xSSC/1% SDS and once in 0.1xSSC/0.5% SDS, for 30 minutes each at 68°C, 
and finally in 2xSSC for 5 minutes at room temperature. The arrays were 
exposed to an imaging plate (BAS-MP 2040S; Fuji, Kanagawa, Japan) for 3-7 
days, after which images of the hybridised arrays were acquired by scanning the 
plate with a phosphorimager (Bio-Imaging Analyser, BAS-2500; Fuji).  
2.4.2. Data analysis 
In order to find the genes that were differently expressed in the patient samples 
as compared to the reference, principal component analysis (PCA) was applied 
to score the genes according to the expression differences (Hilsenbeck et al., 
1999). Before PCA, the data were pre-processed. First, the brightness of the 
hybridisation images was reduced to get the background intensity 
approximately to the same level in all the images. Then the intensities of the 
gene spots were measured using the Atlas Image 1.5 software (Clontech). The 
intensity of each spot on the patient array was compared to the intensity of the 
corresponding spot in the reference array in the following manner. First, the 
background intensity of the hybridisation image was subtracted form all intensity 
values. Next, the intensity of each gene spot in the reference array was subtracted from 
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the corresponding intensity in the patient array to get the intensity difference, 
which represents the expression difference of a given gene between the patient 
sample and the reference. The data was globally normalised by subtracting the 
average of the intensity differences in one array from each intensity difference 
value, standardising the average of intensity differences in all arrays to zero. In 
addition, the variance was standardised to one by dividing each of the 
normalised intensity differences of an array by the standard deviation. 
PCA was applied to normalised intensity differences. By projecting the data 
on the first principal component, each gene was given a score to represent its 
overall expression difference between the patient samples and the reference.  
To describe the differential expression in individual patients, thresholds to 
determine under- and over-expression were used. The thresholds were obtained 
by calculating the percentiles of the pooled expression arrays. The 10th and 90th 
percentiles were used to determine the thresholds, which were normalised 
intensity differences of –5555 and 4005 for under- and over-expression, 
respectively. 
To confirm that over-expression detected in five myeloid-specific genes was 
not caused by the presence of myeloid cells in the patient samples, possible non-
random effect of the proportion of myeloid cells on the expression levels of 
these genes was investigated. The patients were divided into two groups 
according to the proportion of myeloid cells in their bone marrow samples, six 
patients with ≥10% of myeloid cells into one group and eleven with <10% to 
another group. Considering each gene separately, it was checked whether its 
expression level could be used to allocate the sample to the correct myeloid cell 
group. To test the degree of accuracy with which gene expression could predict 
the group assignment, the Receiver Operating Characteristic (ROC) Curve and 
the area under the curve were calculated (Hanley and McNeil, 1982; Swets, 
1988). To check whether this diagnostic accuracy was statistically significant, 
the following randomisation experiment was performed. The group labels of the 
patients were randomly permuted and the diagnostic accuracy calculated for the 
random problem using the same method as for the original data. This 
experiment was repeated 10 000 times.  
2.5. Quantitative real-time reverse transcriptase 
polymerase chain reaction (V) 
The validity of the cDNA array results was confirmed by performing 
quantitative real-time RT-PCR on eight of the genes. The real-time RT-PCR 
experiment was performed on samples from 15 of the 17 patients because not 
enough RNA was available from the other two. RNA (500 ng) was reverse-
transcribed into cDNA from each patient sample and from one of the reference 
pools using the 1st strand cDNA synthesis kit for RT-PCR containing AMV 
enzyme (Roche Diagnostic Corp., Indianapolis, IN, USA).  
The real-time PCR was carried out in the LightCycler rapid thermal cycler 
system (Roche Diagnostics GmbH, Mannheim, Germany). The primers were 
designed and prepared by TIB Molbiol (Berlin, Germany). The PCRs were 
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prepared in a 10 µl volume with 1 µl “Hot Start” reaction mix from the 
LightCycler-FastStart DNA Master SYBR Green I kit (Roche Diagnostics 
GmbH), 2.6 mM MgCl2, 0.5 mM each primer (0.25 mM for the MYC gene) and 
1 µl of diluted cDNA (1:5, 1:10 or 1:50). 
The LightCycler run was started with an initial denaturation at 95°C for 7 
minutes. The cDNA was amplified by performing 45 cycles of denaturation at 
95°C for 15 seconds, annealing at 58-66°C for 5 seconds, and elongation at 
72°C for 10 seconds. To verify the amplification specificity, melting curve 
analyses were performed using an initial denaturation at 95°C for 10 seconds, 
followed by 20 seconds at 55°C, and then slow heating of the samples to 95°C 
at the rate of 0.1°C/s with continuous fluorescence detection. 
Each patient sample was run simultaneously with the reference sample and a 
negative control without cDNA was included in each run. In addition, to obtain 
standard curves for quantification, a dilution series of the β globin gene 
(LightCycler-Control Kit DNA; Roche Diagnostics GmbH) was run in each 
assay according to the manufacturer’s instructions. The relative concentration 
values for each PCR product were calculated using the Second Derivative 
Maximum method included in the LightCycler software. 
In order to compare the results of cDNA array and real-time RT-PCR, the 
logarithmic ratios of patient-to-reference intensities in the array and logarithmic 
ratios of patient-to-reference concentrations in the PCR were calculated. The 
equivalence between the results was visualised by plotting the logarithmic PCR 
ratios against the corresponding logarithmic array ratios. 
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Results 
1. DNA copy number changes in childhood AML (I) 
The results from CGH and standard cytogenetic analysis of the 19 children with 
AML are presented in Table I of Publication I. The karyotypes were retrieved 
from clinical records. Taking into account the limitations of CGH, no 
discrepancies were found between the two methods.  
CGH showed changes in 13 (68%) out of the 19 patients with an average of 
1.9 aberrations per patient (range, 1 to 5). Gains were 2.6 times more frequent 
than losses. Eighteen (72%) of the changes affected a whole chromosome, five 
(20%) a chromosome arm, and only two (8%) of the aberrations were regional. 
The most frequent changes were gains of whole chromosomes 6, 8 and 21, all 
of which were detected three times. Two of the gains of chromosome 21 were 
seen in patients with the Down syndrome. The only losses detected more than 
once were those of whole chromosomes 7 and X, both of which appeared in two 
patients. No high-level amplifications were observed. 
2. DNA copy number changes in childhood ALL (II) 
CGH revealed changes in 45 (63%) out of the 72 patients with a mean of 4.6 
aberrations per patient (range, 1 to 22). All the findings are presented in Figure I 
of Publication II. Gains were about six times more frequent than losses. Table 3 
shows the most frequent gains and losses. Most of the gains (87%) comprised 
whole chromosomes. Regional gains were most frequently observed at 1q with 
minimal common region 1q31-q32 (8.3%). High-level amplifications were 
detected only in two patients, four in one patient (chromosomes 8, 10, 18 and 
21) and one (21q22-qter) in the other. Thus, chromosome 21 was the only 
chromosome with more than one high-level amplification.  
Losses were frequently observed at chromosomal arms 9p and 12p. Nine 
patients (13%) showed loss at 9p with minimal common region 9p22-pter. In 
eight patients (11%), the losses affected 12p with minimal common region 
12p13-pter. In three patients, 9p and 12p were affected simultaneously. 
Table 4 shows a comparison of results obtained by CGH and conventional 
cytogenetic analysis. CGH complemented chromosomal banding in 34 (47%) 
out of the 72 patients. In 25 of these, CGH showed additional changes or 
defined the changes seen in banding analysis. In addition, CGH revealed 
changes in five patients with normal karyotype and in four patients with no 
result in G-banding. In nine patients standard cytogenetics showed unbalanced 
aberrations that were not detected by CGH. One of the patients showed trisomy 
6 in G-banding but no changes in CGH. The result was confirmed by 
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chromosome painting, which showed that the trisomy was present only in 6% of 
the cells, which explains why the aberration was not detected by CGH. 
 
Table 3. The most frequent DNA copy number changes detected in 72 children 
with ALL (II). 
 Chromosome or 
chromosome arm/ 
minimal common 
region 
Number of 
patients 
Frequency 
(%) 
 
GAINS    
- whole chromosome 21 18 25 
   affected 18 16 22 
 X 14 19  
 10 14 19 
 17 14 19  
 14 13 18  
 4 12 17  
 6 12 17  
 8 10 14  
- regional 1q / 1q31-q32 6   8  
LOSSES 9p / 9p22-pter 9 13  
 12p / 12p13-pter 8 11 
 
 
Table 4. Similarities and discrepancies between CGH and chromosome 
banding  analyses in 72 children with ALL (II). 
Findings No of cases   
(Proportion) 
Normal in both techniques 23     (32%) 
Identical changes in both techniques  7      (10%) 
CGH supplemented G-banding 
  -  G-banding unsuccessful / CGH successful 
  -  G-banding normal / CGH abnormal 
  -  CGH gave additional information to G-banding 
 
 4        (6%) 
 5        (7%) 
25     (35%) 
G-banding showed changes not seen in CGH 
  -  CGH unsuccessful / G-banding successful 
  -  G-banding showed balanced translocation 
  -  G-banding showed unbalanced changes not seen in CGH 
 
 - 
 3        (4%) 
 9      (13%) 
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3. Increased copy number of the AML1 gene in 
childhood ALL (III) 
In the CGH study of ALL (II), high-level amplification at chromosome 21 with 
minimal common region 21(q22-qter) was detected in two of the patients. The 
region harbours the AML1 gene that participates in the translocation t(12;21). It 
was therefore investigated whether the copy number of AML1 is increased in 
childhood ALL. 
Forty (36%) of the 112 patients were shown to have at least one extra copy 
of the AML1 gene by FISH (Table I, Publication III). Two of the patients (1.8% 
of all 112 patients) showed high-level amplification of AML1 in most of the 
cells, one with at least 10-15 copies of the gene and the other with six copies. 
One patient had four copies of AML1 in most of the cells, but at least five 
copies in 6% of the cells. In 20 patients (18%) four copies of the gene were 
detected in at least 40% of the cells. Seventeen patients (15%), including two 
patients with the Down syndrome, showed three copies of AML1. 
The TEL-AML1 fusion was detected in 31 (28%) of the 112 patients. The 
fusion was present in seven (18%) of the 40 patients with extra AML1 copies 
(Table I, Publication III) and in 24 (33%) of the 72 patients with no extra copies 
of the gene. Six of the 31 patients with the fusion showed two copies of the 
fusion gene in part of the fusion-positive cells, and in one patient, 2-4 copies of 
the fusion gene were seen in all of the cells. The other TEL allele was deleted in 
19 (61%) of the 31 fusion-positive patients but only in three (4%) of the 81 
fusion-negative patients.  
In two patients with high-level amplification of AML1, a derivative of chromosome 
21 was seen in conventional cytogenetic analysis. The extra copies of the gene were 
located in the derivative chromosome. In the patient with 10-15 AML1 copies, the 
extra copies were tandemly located in two sites of the derivative, and in the patient 
with six copies, as two separate tandem duplicates. Chromosome painting with a 
chromosome 21-specific probe stained the whole der(21) of the patient with 10-15 
copies and four distinct regions in der(21) of the patient with six copies. In the patient 
with 4-5 copies of the gene, the copies were located in different chromosomes. The 
poor quality of the metaphases with five copies made it impossible to distinguish the 
type and size of the chromosomes. In addition, the karyotype of the patient was 
incomplete. According to chromosome painting analysis the maximum number of 
copies of chromosome 21 was four. No material from this chromosome was seen in 
any other region. 
Metaphases were studied also from three patients with 3-4 copies of AML1. 
In all three patients, the gene copies were located in separate chromosomes, 
probably in copies of chromosome 21. Karyotypes from conventional 
cytogenetic analysis were available from twelve of the patients with 3-4 AML1 
copies (Table I, Publication III). Four of them showed an extra chromosome 21 
in G-banding. Two of these patients had the Down syndrome. 
CGH results were available for 26 of the 112 patients and eleven of them 
showed a gain at chromosome 21 (Table I, Publication III). All of these eleven 
patients also showed extra copies of the AML1 gene in FISH. In the three 
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patients with more than four copies of AML1 (10-15, 6 or 4-5), a high-level 
amplification at chromosome 21 was seen in CGH. 
4. FISH analysis of the TEL and AML1 genes in 
ALL patients with loss at 12p (IV) 
The short arm of chromosome 12 showed a frequent loss in the ALL patients by 
CGH (II). The minimal common region of the losses (12p13-pter) contains the 
TEL gene (12p13) that is fused to AML1 in t(12;21). Because the non-
translocated TEL allele is deleted in most of the patients with t(12;21), the 
association of this translocation and the TEL deletion with the 12p losses was 
investigated. 
FISH results of nine patients who showed a loss at 12p in CGH studies are 
presented in Table IV of Publication IV. Eight of the nine patients showed the TEL-
AML1 fusion and the deletion of the non-translocated allele of the TEL gene. In one 
patient, the fusion was not seen, but the other allele of TEL was deleted. In seven of 
the eight fusion-positive patients, the fusion was detected in most interphase cells (74-
100%) and in one patient in 27% of the interphase cells. The non-translocated TEL 
allele was deleted in all fusion-positive cells in five patients, and in about 60% of the 
fusion-positive cells in three patients. The 12p deletion was detected by conventional 
cytogenetics only in one of the cases.  
Seven of the nine patients survived in continuous complete remission with a 
median follow-up of 74 months (range, 51-121 months). Patients with 12p loss 
showed a trend to better overall survival compared to 70 other patients with no 
12p loss. In addition, all patients with 12p loss showed good early response to 
therapy, precursor-B immunophenotype and L1 morphology, and only one of 
them had high (>50x109/litre) WBC at diagnosis. None of the nine patients were 
hyperdiploid. 
5. Gene expression in childhood ALL (V) 
The gene expression data was analysed using the PCA method. Each of the 415 
genes in the array was given a score, representing the difference in its 
expression between the test and reference samples. The genes with the highest 
scores were considered to be over-expressed and those with the lowest scores 
under-expressed as compared to the reference. Based on the PCA projection, 25 
(6%) most over-expressed genes were chosen for closer observation. The genes 
are listed in Table III of Publication V with their functions and the types of 
haematopoietic cell that normally express the genes. The expression pattern of 
these genes in all the patients is shown in Figure II of Publication V. The number of 
patients with over-expression of the genes ranged from 7 to 17. The 20 genes that 
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were ranked to be the most under-expressed are presented in Table IV of 
Publication V. 
The cDNA array results were confirmed by real-time RT-PCR for seven of 
the over-expressed genes (ERG, AML1, ENG, TEL, MLLT2, DAPK1 and MYC) 
and for one under-expressed gene (BAX; BCL2-associated X protein). Overall, 
the PCR results agreed well with the cDNA array results. 
Five of the 25 most over-expressed genes (S100A12, RNASE2, GCSFR, 
PRTN3, and CLC) are known to be expressed in myeloid cells but not in B- 
lymphoid cells. To ascertain that the over-expression of these myeloid-specific 
genes was not caused by myeloid cells present in the bone marrow samples, it 
was investigated whether a non-random effect exists between the proportion of 
myeloid cells and the expression of these genes. As no such effect could be 
demonstrated (ROC = 0.29-066, p = 0.13-0.46), it was concluded that the small 
amount of myeloid cells did not have a significant effect on the expression level 
of the myeloid-specific genes. 
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Discussion 
1. Comparative genomic hybridisation and 
conventional cytogenetics in childhood AML (I) 
In the present study of 19 children with AML, the concordance between the 
results obtained by CGH and conventional cytogenetics was high. 
Chromosomal banding analysis was successful, and CGH did not give 
additional information to the karyotypes obtained. On the other hand, in 13 
patients (68%) the banding technique detected changes not seen in CGH. These 
changes included balanced translocations, inversions and marker chromosomes. 
Moreover, polyploidy and aberrant subclones were detected by conventional 
cytogenetics. 
In one previous study of eight adults with AML, CGH complemented 
conventional cytogenetics only in one case with no result in banding analysis 
(Bentz et al., 1995). However, in one previous and two later studies of adult 
AML, CGH was found to be successful in unravelling complex karyotypes, 
especially in identifying the composition of marker chromosomes (El-Rifai et 
al., 1997a; Kim et al., 2001; Verdorfer et al., 2001). Overall, the karyotypes in 
those studies were considerably more complex than in the present study and 
contained numerous marker chromosomes. In the present study, marker 
chromosomes were only seen in two of the patients. Different degrees of 
complexity in karyotypes may explain why CGH failed to complement the 
banding analysis in the present study like it did in adult AML studies. In 
addition, in all three studies of adult AML, deletions of chromosomal arms 5q 
and 7q were among the most frequent changes both by standard cytogenetics 
and CGH, whereby CGH yielded more details of the deletions found by the 
banding analysis. These aberrations are more rare in childhood AML, and 
neither of them was found in the present study (Heim and Mitelman, 1995; 
Perkins et al., 1997). On the other hand, the balanced translocation t(8;21), the 
most common alteration in childhood AML, is more frequent in children than in 
adults (Heim and Mitelman, 1995). Furthermore, high-level amplifications, not 
observed in the present study, appear more often in adult AML (Alitalo et al., 
1985; Asker et al., 1988; Tanaka et al., 1993; Park et al., 2000; Streubel et al., 
2000; Andersen et al., 2001). One high-level amplification has been reported in 
a later CGH study of adults (Verdorfer et al., 2001) and two high-level 
amplifications in another (Kim et al., 2001). Considering these differences 
between childhood and adult AML, the CGH method may be more useful in the 
diagnostics of adult patients. 
In Study II, CGH gave additional information to standard cytogenetics for a 
great proportion of the patients with ALL. The main reasons why CGH 
supplemented banding analysis in childhood ALL patients but not in the 
childhood AML patients are probably the differences between the frequency of 
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numerical changes, and the number and quality of the metaphases obtained. In 
childhood ALL, the proliferation rate of the blasts is usually weaker and 
morphology of the chromosomes poorer. Poor quality of metaphases makes it 
often impossible to identify the extra chromosomes frequently occurring in 
ALL, resulting in incomplete karyotypes.  
On the basis of these results, there seems to be no need to apply CGH to the 
routine diagnostics of children with AML. However, CGH can be of great help 
in cases with no metaphases available for the banding analysis and in resolving 
complex karyotypes in cases with incomplete cytogenetic results.  
2. CGH as a support of conventional cytogenetics in 
childhood ALL (II) 
In about half of the 72 ALL cases studied, CGH supplemented chromosomal 
banding analysis. CGH detected copy number changes in five (7%) patients 
with a normal karyotype and defined changes or detected additional alterations 
in 25 (35%) patients with an abnormal karyotype. Furthermore, changes were 
detected by CGH in four (6%) cases, which yielded no metaphases for G-
banding.  
In most of the cases, the cytogenetic analysis succeeded in estimating the 
number of chromosomes, but the morphology of the chromosomes was often 
too poor to enable recognition of the chromosomes that were gained or lost. 
CGH was successful in identifying these chromosomes as well as in clarifying 
the composition of the marker chromosomes. In addition, CGH revealed small 
losses not detected by banding analysis. CGH turned out to be especially 
valuable in finding FISH markers for patient follow-up. Thus, CGH lends 
significant support to conventional cytogenetic analysis in childhood ALL. This 
is in agreement with two previous and several later CGH studies of childhood 
ALL (Karhu et al., 1997; Paszek-Vigier et al., 1997; Haas et al., 1998; Wong et 
al., 1998; Jarosová et al., 2000; Scholz et al., 2001). The clear supplementary 
benefits of CGH to the banding technique are mainly explained by the high 
frequency of hyperdiploidy, poor quality of metaphases and low proliferation 
rate of leukaemic blasts in childhood ALL. Accordingly, it is highly 
recommended to perform CGH routinely for children at the diagnostic stage of 
ALL. 
In 12 (17%) of the 72 patients, conventional cytogenetic analysis showed 
changes that were not detected by CGH. In three (4%) of the cases, 
chromosomal banding revealed a balanced translocation, which CGH is unable 
to detect because the translocation leaves the DNA copy number unchanged. 
The failure of CGH to detect the unbalanced aberrations, found in nine (13%) 
cases by G-banding, is probably explained by aberrations that were present only 
in subclones that are beyond the detection capacity of CGH (minimum 50% of 
the cells), as confirmed by FISH in one case. Because of its limitations, CGH 
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cannot replace standard cytogenetics, which continues to be an important 
diagnostic tool in ALL. 
3. DNA copy number changes in childhood ALL (II) 
3.1. Gains 
The most common aberrations shown by CGH were gains of whole 
chromosomes. This outcome could be expected in view of the high frequency of 
hyperdiploidy in childhood ALL. Chromosome 21 (25%) was gained most 
frequently. Other chromosomes with frequent whole chromosome gains were 
18, X, 10 and 17 (19-22%) and, at lower frequencies, chromosomes 14, 4, 6 and 
8 (14-18%). The results are in agreement with previous findings by 
conventional cytogenetics, as well as with two previous and several later CGH 
studies (Raimondi et al., 1992; Raimondi et al., 1996; Karhu et al., 1997; 
Paszek-Vigier et al., 1997; Haas et al., 1998; Larramendy et al., 1998; Jarosová 
et al., 2000; Scholz et al., 2001). Table 5 summarises the most frequent findings 
in all the CGH studies. 
Regional gains were rare. The most frequent were gains at 1q with minimal 
common region 1q31-q32, observed in six (8%) of the patients. The gain of 
1q24-qter in three patients was probably a result of the unbalanced translocation 
t(1;19), a well-known translocation in ALL (Heim and Mitelman, 1995). 
Unbalanced translocations can easily be missed in standard cytogenetics due to 
poor quality of metaphases. In these cases, CGH would help to reveal them. 
High-level amplifications were found only in two patients, which supports the 
concept of high-level amplifications being rare in childhood ALL. In the other 
CGH studies, only four patients with altogether six high-level amplifications were 
reported (Karhu et al., 1997; Larramendy et al., 1998; Wong et al., 1998). In the 
present study, the only chromosome with more than one high-level amplification 
was chromosome 21. In one patient the whole chromosome was amplified and in 
the other the affected region was 21q22-qter. Interestingly, the chromosomal band 
21q22 contains the AML1 gene, which is fused to the TEL gene in the t(12;21) 
translocation. Later, additional high-level amplifications affecting the whole 
chromosome 21 have been found in one of 36 patients and two of 14 patients 
(Larramendy et al., 1998; Wong et al., 1998).  
 
  
 
 
Table 5. Summary of the frequencies (%) of most frequent CGH findings in eight publications of childhood 
ALL. 
 
Reference Most frequent gains Most frequent losses 
(No. of patients) X 1q 4 6 8 10 14 17 18 21 6q 9p 12p 13q 
 
A (72) 
 
19 
 
8 
 
17 
 
17 
 
14 
 
19 
 
18 
 
19 
 
22 
 
25 
 
3 
 
13 
 
11 
 
4 
B (36) 42 11 31 31 8 36 28 28 33 44 - 6 14 - 
C (72) 28 3 17 18 11 15 19 7 22 24 1 - - - 
D (13) 38 - 15 8 23 23 23 15 23 31 8 - - - 
E (65) 31 9 23 25 8 26 22 25 28 35 9 18 11 9 
F (71) 15 8 11 15 6 20 15 14 15 20 4 14 8 1 
 
Total A-F 
(329) 
 
26 
 
7 
 
18 
 
19 
 
10 
 
22 
 
20 
 
17 
 
23 
 
28 
 
4 
 
10 
 
8 
 
3 
 
G (14)* 
 
36 
 
7 
 
29 
 
43 
 
29 
 
36 
 
36 
 
21 
 
43 
 
36 
 
- 
 
14 
 
- 
 
- 
H (14)** 93 - 71 86 57 79 86 71 11 100 - - - - 
 
A, Study II; B, Larramendy et al. 1998; C, Paszek-Vigier et al. 1997; D, Karhu et al. 1997; E,  Jarošová et al. 2000;     
F, Scholz et al. 2001; G, Wong et al. 1998; H, Haas et al. 1998; *selected group of patients showing unbalanced 
changes by standard cytogenetics; **selected group of patients showing hyperdiploidy by standard cytogenetics. 
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3.2. Losses 
The two most frequent losses affected 9p in nine patients (13%) and 12p in eight 
patients (11%) with minimal common regions 9p21-pter and 12p13-pter, respectively. 
Surprisingly, no losses at 9p or 12p were detected in three CGH studies (Karhu et al., 
1997; Paszek-Vigier et al., 1997; Haas et al., 1998). More recently, however, losses at 
9p and 12p have been reported in three and two studies, respectively (Table 5) (Wong 
et al., 1998; Jarosová et al., 2000; Scholz et al., 2001). The aberrations of 9p have 
been shown to be associated with poor overall survival (Heerema et al., 1999).  The 
frequencies of 9p loss (18% and 14%) and 12p loss (11% and 8%) in the studies by 
Jarosová et al. (2000) and Scholz et al. (2001) showing both aberrations corresponded 
well with the findings of the present study. Jarosová et al. (2000) also showed 
relatively frequent losses at 13q (9%), 6q (9%) and 7p (8%), findings that were less 
common in the other studies, including the present study (Table 5). The losses at 9p 
and 12p, including deletions and unbalanced translocations, had both previously been 
seen in about 8% of the patients using conventional cytogenetics (Raimondi, 1993; 
Raimondi et al., 1997). Furthermore, 9p and 12p are the regions that most frequently 
show LOH in childhood ALL (in about 30-40% and 25-30% of the patients, 
respectively) (Takeuchi et al., 1995; Baccichet et al., 1997; Chambon-Pautas et al., 
1998). The absence of these losses in some of the CGH studies is probably due to a 
methodological failure. This emphasises how important it is to control the technical 
aspects when using the method. 
Despite the rather high frequency of losses at 9p and 12p in standard 
cytogenetic studies by Raimondi´s group (Raimondi, 1993; Raimondi et al., 
1997), only one of the nine 9p losses and two of the eight 12p losses were 
revealed by banding analysis in the present study. Also, in a later study by 
Jarosová et al. (2000), only two 9p losses out of 12 and one 12p loss out of 
seven detected in CGH were seen by chromosome banding. In addition, CGH 
helped to define the region of the losses seen in cytogenetic analysis. 
The minimal common region of the 9p losses contains the chromosomal 
band 9p21 with two tightly linked tumour suppressor genes, CDKN2A and 
CDKN2B. Both genes are deleted, usually simultaneously, in about 40% of 
children with ALL [(Drexler, 1998) and references therein]. Other candidate 
tumour suppressor genes in the region, often co-deleted with CDKN2A and 
CDKN2B, are MTAP (methylthioadenosine phosphorylase) and IFN (interferon) 
gene cluster (Dreyling et al., 1995).  
The minimal common region of the 12p losses involves the chromosomal 
band 12p13 with the TEL gene. One TEL allele is deleted in about 75% of the 
patients with the TEL-AML1 fusion (Cavé et al., 1997), which is present in 
about 25% of the patients (Romana et al., 1995b; Shurtleff et al., 1995; Liang et 
al., 1996; McLean et al., 1996; Borkhardt et al., 1997). The hemizygous 
deletion of CDKN1B (KIP1; p27), mapped to 12p12, is also common in 
childhood ALL (Pietenpol et al., 1995; Takeuchi et al., 1995; Komuro et al., 
1999). Furthermore, hypermethylation of LRP6 (low-density lipoprotein-related 
protein 6) in 12p12.3 has been reported in two patients with hemizygous 12p 
deletion (Baens et al., 1999). 
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The much lower frequency of the 9p- and 12p losses seen in CGH, as 
compared to the frequencies of LOH and gene deletions in the region, is 
explained by the inability of CGH to detect deletions smaller than 3-10 Mb 
(Kallioniemi et al., 1994; Kirchhoff et al., 1999). However, a great proportion 
of the deletions seem to be large enough for the resolution of the method. 
Because these deletions seem to be significant prognostic markers, it is crucial 
to detect them.  
4. Amplif ication of the AML1 gene in childhood 
ALL (III) 
CGH revealed high-level amplifications at chromosome 21 in two children with 
ALL (Study II). Chromosome 21 contains the AML1 gene involved in t(12;21). 
The aim of the present study was to investigate whether AML1 is a target of 
amplification in childhood ALL.  
Three (2.7%) of the 112 patients studied showed high-level amplifications of 
AML1 with 10-15, six, and five copies of the gene. In all of these patients, high-
level amplification was also detected at chromosome 21 by CGH, the minimal 
common region being 21q22-qter. In two patients with 10-15 and six copies of 
AML1, the extra copies were found to be located in tandem in two distinct sites 
of a derivative chromosome 21. Thus, the increase in the copy number seems to 
have occurred through intrachromosomal amplification, followed by duplication 
of the region with tandem repeats of the gene. 
The present study was the first publication to describe high-level 
amplification of AML1 in ALL. In addition, gene amplification had not been 
reported in childhood ALL before. Later the finding has been confirmed by 
several other studies, which demonstrated childhood ALL cases with 
amplification of AML1 (Busson-Le Coniat et al., 2001; Dal Cin et al., 2001; Ma 
et al., 2001; Mathew et al., 2001; Nordgren et al., 2002). In the reports the copy 
number of the gene varied from five to 15. The frequency seen in the present 
study agrees with the findings of Nordgren et al. (2002) who detected AML1 
amplification (7-15 copies) in two out of 70 patients studied. In addition to 
childhood ALL, the amplification of AML1 has been reported in an adult with 
myelodysplastic syndrome (Kakazu et al., 1999), and recently also in an adult 
with AML (Streubel et al., 2001). 
Thirty-seven (33%) out of the 112 patients showed three or four copies of 
AML1. Probably all or almost all of these patients had one or two extra copies 
of whole chromosome 21. This is supported by the high frequency of gains of 
chromosome 21 by CGH (Table 5) and conventional cytogenetics (Raimondi et 
al., 1992, 1996; Berger, 1997; Karhu et al., 1997; Paszek-Vigier et al., 1997; 
Haas et al., 1998; Larramendy et al., 1998; Jarosová et al., 2000; Scholz et al., 
2001; Study II). 
In the present study, none of the patients with high-level amplification of 
AML1 showed the TEL-AML1 fusion. The amplification was, however, reported 
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in a fusion-positive patient by Ma et al. (2001). The amplification was present 
both in cells with and without the fusion, suggesting that it had occurred before 
the translocation. The frequency of the TEL-AML1 fusion in the patients with 3-
4 copies of AML1 was clearly lower (19%) than in those with two copies (33%). 
This agrees with previous studies, which showed that the patients with the 
fusion have much lower frequency of hyperdiploidy (51+) (Shurtleff et al., 
1995; Raimondi et al., 1997). The result is further supported by a report of the 
absence of TEL-AML1 fusion in eleven patients with the Down syndrome 
(Lanza et al., 1997). 
The amplification of AML1 is likely to increase the expression of the gene. 
Busson-Le Coniat et al. (2001) studied three patients with five copies of the 
AML1 gene and searched for point mutations in its exons 3-5, where all the 
published point mutations are located (Osato et al., 1999; Song et al., 1999). 
They detected no point mutations in these exons, which suggests that the 
amplified AML1 was of wild-type. Over-expression of the AML1B isoform has 
been shown to cause neoplastic transformation in fibroblasts (Kurokawa et al., 
1996) and to shorten the cell cycle in myeloid progenitor cells (Strom et al., 
2000) suggesting that the amplification of wild-type AML1 has a pathogenic 
effect. Further studies are, however, needed to investigate whether AML1 is 
mutated when amplified, and also whether the 21q22-qter amplicon harbours 
other leukaemia-specific genes. 
5. Association of loss at 12p with the TEL-AML1 
fusion in childhood ALL (IV) 
In Study II, loss at 12p was frequently observed in ALL patients by CGH. In 
order to investigate whether this loss is associated with the TEL-AML1 fusion 
and the deletion of the other TEL allele, FISH was performed for nine patients 
with the 12p loss. Eight of the nine patients showed the TEL-AML1 fusion with 
the deletion of the non-translocated TEL allele. This proportion is slightly 
higher than in two previous studies using standard cytogenetics, in which the 
TEL-AML1 fusion was detected in 17 (68%) of 25 (Raimondi et al., 1997) and 
six (67%) of nine (O'Connor et al., 1998) patients with loss of 12p material. 
Furthermore, 15 (94%) of 16 (Raynaud et al., 1996) and 34 (81%) of 42 (Cavé 
et al., 1997) patients with LOH at the TEL locus were reported to show the 
TEL-AML1 fusion.  
In three patients of the present study, the TEL deletion was present only in 
part of the cells with the fusion. This supports previous studies that show the 
deletion to be a secondary event after the translocation (Raynaud et al., 1996; 
Romana et al., 1996; Cavé et al., 1997). 
In the present study, one of the nine patients did not show the TEL-AML1 
fusion but had lost one TEL allele. Because point mutations of TEL in cases 
with LOH at 12p as well as homozygous deletions of TEL seem to be rare (Sato 
et al., 1995; Stegmaier et al., 1996), CDKN1B and/or another putative tumour 
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suppressor genes in this region were probably co-deleted with TEL in this 
patient (Pietenpol et al., 1995; Baens et al., 1999). 
In the present study, the 12p loss seemed to be associated with favourable 
prognostic features. All the patients had good early response to therapy, L1 
morphology and precursor-B immunophenotype. In addition, the patients with 
12p loss showed a trend toward a better overall survival. This trend is likely to 
be related with the TEL-AML1 fusion, which has been associated with 
favourable outcome in most studies (Liang et al., 1996; McLean et al., 1996; 
Borkhardt et al., 1997; Rubnitz et al., 1997b, c; Loh et al., 1998; Maloney et 
al., 1999a; Rubnitz et al., 1999a). Some studies have, however, questioned the 
prognostic significance of the fusion (Harbott et al., 1997; Seeger et al., 1998, 
2001). The discrepancies between the findings are probably due to differences 
in treatment (Loh et al., 1998). 
6. Gene expression in childhood ALL (V) 
Gene expressions of a total of 415 genes related to normal or abnormal function 
of blood cells and their precursors were analysed in the leukaemic blasts of 17 
children with precursor-B ALL using cDNA arrays. Because the number of B-
lineage cells in normal bone marrow is very limited, normal mature B cells 
from palatine tonsils were used as the reference. 
At least 16 out of the 20 most under-expressed genes (Table IV, Publication 
V), including LCP1 (lymphocyte cytosolic protein 1), CD83, LYN (v-yes-1 
Yamaguchi sarcoma viral related oncogene homolog), SPIB (Spi-B 
transcription factor) and CD48 are known to be expressed in mature B cells 
(Hamaguchi et al., 1982; Yokoyama et al., 1991; Zhou et al., 1992; Su et al., 
1996; Hibbs and Dunn, 1997). Although some of the under-expressed genes are 
also known to be expressed in the precursors of B cells, the under-expression of 
most of them was probably related to the use of mature B cells as reference for 
the precursor-B cell type of leukaemia. Consequently, closer examination of the 
results was focussed on over-expressed genes. 
The 25 most over-expressed genes (Table III, Publication V) included four 
genes that are expressed only in the cells of the myeloid lineage: GCSFR, 
PRTN3, RNASE2 and CLC (Weller et al., 1982; Bories et al., 1989; Nagata and 
Fukunaga, 1991; Rosenberg, 1998). In addition, over-expression was detected 
in S100A12, which encodes a peptide released from sensory nerve endings to 
bone marrow (Bjurholm et al., 1988), but it is also expressed in myeloid cells 
(Guignard et al., 1995; Robinson and Hogg, 2000). Using statistical tests it was 
shown that the small amount of myeloid cells in the bone marrow samples of 
the patients did not significantly affect the expression level detected in these 
myeloid-specific genes. It was therefore concluded that the over-expression of 
myeloid-specific genes was related to their up-regulation in the malignant cells.  
The results are in agreement with flow-cytometric studies that show variable 
degrees of phenotypic expression of myeloid markers in a large proportion of the 
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patients with B-lineage ALL (Pui et al., 1991). Out of the 17 patients of the 
present study, immunophenotyping showed expression of CD34 and CD13 
antigens in 16 and 10 patients, respectively. The array method detected over-
expression of CD34 and CD13 in 15 and six patients, respectively. 
Out of the five over-expressed myeloid-specific genes, GCSFR and PRTN3 encode 
proteins that are known to regulate cell proliferation. Thus, these genes are good 
candidates to have a role in the pathogenesis of ALL. These two genes function in a 
same pathway. GCSFR encodes a receptor for G-CSF, a myeloid growth factor, and 
PRTN3 is known to be up-regulated by G-CSF (Suda et al., 1987; Lutz et al., 2000). 
GCSFR has been reported to be up-regulated in precursor-B ALL by the t(1;19)-
specific oncoprotein E2A-PBX1, providing evidence that over-expression of GCSFR 
may be related to leukemogenesis (de Lau et al., 1998). Constitutive over-expression 
of PRTN3 causes G-CSF independent growth of myeloid progenitors, the G-CSF 
receptor being essential for this process (Lutz et al., 2000). PRTN3 has not previously 
been reported to be associated with ALL. 
One of the numerous functions of S100A12 is to inhibit B-cell development 
(Fernandez et al., 2000). Over-expression of S100A12 was previously detected 
in CLL using cDNA arrays (Aalto et al., 2001). No involvement of S100A12 in 
ALL has been reported before. 
Because mature B cells were used as reference for leukaemic blasts derived 
from precursor-B cells, over-expression was expected in the genes that are more 
highly expressed in the early stages of B-cell development. Accordingly, over-
expression was detected in genes that function in the rearrangement of 
immunoglobulin genes (TDT and RAG1) and genes encoding cell surface 
antigens of lymphoid precursors (CD34, SPN, CD9 and CALLA). In addition, 
the expression of murine homologues of ERG, TEL and MLLT2 has been found 
to be higher in B-cell precursors as compared to mature B cells (Baskaran et al., 
1997; Anderson et al., 1999). All three are genes that encode transcription 
factors and are rearranged in recurrent translocations of leukaemias (Golub et 
al., 1995; Heim and Mitelman, 1995). Furthermore, the expression of MYC has 
been reported to correlate with the stage of differentiation and the proliferation 
activity of B cells (Larsson et al., 1991). On the other hand, MYC has been 
shown to be up-regulated as a result of translocations in Burkitt lymphoma and 
leukaemia, and T-cell ALL, and by amplification or other mechanisms in AML 
and in various solid tumours (Alitalo et al., 1985; Erikson et al., 1986; Preisler 
et al., 1987; Baer et al., 1992; Heim and Mitelman, 1995). 
Interestingly, AML1 was one of the most over-expressed genes. The previous 
finding of high-level amplification of AML1 by FISH (Study III) suggests that 
over-expression of the gene may be related to leukemogenesis. Furthermore, as 
mentioned in Chapter 4, over-expression of AML1 shortens the cell cycle in 
myeloid cells and causes transformation in fibroblasts (Kurokawa et al., 1996; 
Strom et al., 2000). However, haploinsufficiency of AML1 has been reported to 
cause autosomal dominant platelet disorder with predisposition to AML (Song 
et al., 1999). What has to be taken into account is that AML1 encodes a number 
of alternative transcripts with different and even opposite functions, and that 
besides the absolute amount of AML1 mRNA, the relative amounts of distinct 
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mRNA forms affect the function of the gene (Miyoshi et al., 1995; Levanon et 
al., 2001). The primers that were used recognise several AML1 mRNA 
isoforms, thus their individual expression could not be determined.  
Over-expression was also detected in LCP2, which encodes an adapter 
protein in precursor-T and T-cell receptor signalling [(Rudd, 1998) and 
references therein]. The gene has been found to be up-regulated in a Burkitt 
lymphoma B-cell line after B-cell receptor cross-linking, and the protein has 
been suggested to function in B-cell receptor signalling as well (Mizuno et al., 
1996; Nakayama et al., 2000). LCP2 has been found to be over-expressed in 
CLL using the cDNA array method (Aalto et al., 2001). The gene has not been 
reported to be associated with ALL. 
The present study was the first publication about the expression of FGF6 in 
leukaemic blasts of ALL. Because FGF6 does normally not seem to be 
expressed in bone marrow at all, it is highly probable that the over-expression 
detected in the gene is related to its up-regulation in leukaemic blasts. 
Expression of FGFR1 and FGFR4, which encode the receptors of FGF6, has 
been reported in precursor-B cell lines, and expression of FGFR1 also in mature 
B cells (Bikfalvi et al., 1992; Allouche et al., 1995; Ornitz et al., 1996). FGF6 
in turn has been seen to up-regulate the expression of FGFR1 in myoblasts 
(Pizette et al., 1996). Interestingly, over-expression of FGFR1 was detected in 
five out of the 12 patients showing over-expression of FGF6, but in none of the 
patients without FGF6 over-expression. FGFR1 is rearranged in several 8p12 
translocations leading to fusion proteins with constitutive tyrosine kinase 
activity of FGFR1 in a myeloproliferative disorder generally progressing to 
AML (Popovici et al., 1998, 1999; Guasch et al., 2000). In addition, over-
expression of FGFR1 was found in the absence of these translocations in AML 
patients using cDNA arrays (Larramendy et al., 2002). Neither FGF6 nor 
FGFR1 have been connected to ALL before. 
The number of genes in the present study was very limited and restricted to genes 
known to have some role in haematopoiesis, in the function of blood cells or in blood 
disorders. The expression of other types of gene, such as those functioning in cell 
cycle or apoptosis, is also likely to be altered in childhood ALL. Probably because of 
the difficulties in obtaining a relevant reference, the DNA array studies of childhood 
ALL have so far been focussed mostly on classification and not on identifying genes 
abnormally expressed in the leukaemic blasts (Rozovskaia et al., 2001; Armstrong et 
al., 2002; Yeoh et al., 2002). Yeoh et al. (2002) performed a comprehensive study of 
360 patients using arrays with 12 600 genes but without using any reference. Chen et 
al. (2001), on the other hand, purified precursor-B cells and used them as reference, 
but only four patients were studied. A study with large number of genes and patients 
using precursor-B cells as reference would greatly enhance our knowledge about the 
changes in gene expression in precursor-B cell ALL. 
The number of patients in the present study was too small to perform 
classification studies. In addition, a larger number of patients will be required to 
study whether the expression levels of the genes correlate with some clinical 
features. The study of the possible pathogenic and prognostic roles of the genes 
could be focussed to the most interesting ones and be performed using a less 
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complicated method with lower expenses, such as real-time RT-PCR. The 
requirement of smaller amount of RNA in real-time RT-PCR could also 
enhance the possibility to use precursor-B cells as a reference. 
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Summary and conclusions 
In childhood AML, the CGH results were well in concordance with the 
karyotypes obtained by chromosomal banding analysis. However, CGH did not 
complement the results of conventional cytogenetics. Although CGH is 
certainly helpful in the cases with complex karyotypes, the results do not 
advocate performing CGH routinely for all children with AML. 
In childhood ALL, by contrast, CGH was shown to supplement standard 
cytogenetics in about half of the patients studied, especially by identifying the 
chromosomes gained in hyperdiploid cases. The method clearly facilitated the 
finding of markers for disease follow-up by FISH. The use of CGH is thus 
highly recommended to support conventional cytogenetics when studying 
children at the diagnostic stage of ALL. The difference in the utility of the 
method between the two forms of acute leukaemia is mostly explained by the 
higher frequency of numerical changes in ALL and the better success rate of 
standard cytogenetics in AML.  
The most common DNA copy number changes in childhood ALL were gains 
affecting whole chromosomes 21, 18, X, 10, 17, 14, 4, 6 and 8 (14%-25%). 
Regional gains were rare, the most frequent of them being gains at 1q (8%). 
High-level amplifications were detected only in two patients (3%). 
Chromosome 21, with minimal common region 21q22-qter, was the only one 
involved in both of these cases. Two frequent losses affected chromosomal 
arms 9p (13%) and 12p (11%) with minimal common regions 9p22-pter and 
12p13-pter, respectively. Further studies with larger patient material are needed 
for the evaluation of prognostic significance of the individual CGH findings. 
The AML1 gene was shown to be highly amplified in three (2.7%) of 112 
children with ALL. In all of the three patients, high-level amplification at 21q 
was detected by CGH. In addition, one or two extra copies of AML1 were 
detected in 33% of the patients studied, probably in consequence of the gain of 
whole chromosome 21, which was found to be the most frequent gain by CGH. 
The frequency of the TEL-AML1 fusion was lower in the patients with extra 
AML1 copies (18%) than in other patients (33%). Study III was the first 
publication of high-level amplification of AML1 in ALL, and this was also the 
first gene amplification reported in childhood ALL.  In order to understand the 
possible role of the amplification in the pathogenesis of ALL, it should be 
investigated whether AML1 is mutated in the cases with amplification and 
whether the amplified region harbours some other gene(s) with possible 
leukaemic effect. 
The loss at 12p detected by CGH was found to be strongly associated with 
the TEL-AML1 fusion and the deletion of another TEL allele in childhood ALL. 
Eight of nine patients with 12p loss showed the TEL-AML1 fusion and the 
deletion of the non-translocated TEL allele. One TEL allele was lost also in one 
patient without the fusion. In addition, the results support the association of 12p 
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aberrations and the TEL-AML1 fusion with favourable prognostic features and 
good overall survival in children with ALL. 
The cDNA array study provided novel information about gene expression in 
the malignant cells of childhood ALL. Several myeloid-specific genes 
(S100A12, RNASE2, GCSFR, PRTN3 and CLC) were shown to be up-regulated 
in leukaemic blasts. Interestingly, AML1, whose high-level amplification was 
demonstrated by FISH, was over-expressed in comparison to the B-cell 
reference. The most over-expressed genes included also LCP2 and FGF6. The 
data obtained can be utilised in further studies with a larger number of patients 
and using other techniques, to investigate which of the findings are related to 
the pathogenesis and/or prognosis of childhood ALL. 
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